

Mien-Chie Hung

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9248663/publications.pdf>

Version: 2024-02-01

713
papers

74,120
citations

281

140
h-index

877

243
g-index

732
all docs

732
docs citations

732
times ranked

73891
citing authors

#	ARTICLE	IF	CITATIONS
1	PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. <i>Cancer Cell</i> , 2004, 6, 117-127.	16.8	1,693
2	Dual regulation of Snail by GSK-3 β -mediated phosphorylation in control of epithelial \rightarrow mesenchymal transition. <i>Nature Cell Biology</i> , 2004, 6, 931-940.	10.3	1,459
3	Requirement for neuregulin receptor erbB2 in neural and cardiac development. <i>Nature</i> , 1995, 378, 394-398.	27.8	1,165
4	The neu oncogene encodes an epidermal growth factor receptor-related protein. <i>Nature</i> , 1986, 319, 226-230.	27.8	1,090
5	Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. <i>Cell</i> , 1986, 45, 649-657.	28.9	1,034
6	Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. <i>Nature Cell Biology</i> , 2001, 3, 245-252.	10.3	999
7	Nuclear localization of EGF receptor and its potential new role as a transcription factor. <i>Nature Cell Biology</i> , 2001, 3, 802-808.	10.3	950
8	An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer. <i>Cancer Research</i> , 2008, 68, 6084-6091.	0.9	916
9	Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 269-280.	4.3	858
10	HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. <i>Nature Cell Biology</i> , 2001, 3, 973-982.	10.3	850
11	I β B Kinase Promotes Tumorigenesis through Inhibition of Forkhead FOXO3a. <i>Cell</i> , 2004, 117, 225-237.	28.9	823
12	Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 3297-3302.	1.6	795
13	β -Catenin, a novel prognostic marker for breast cancer: Its roles in cyclin D1 expression and cancer progression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 4262-4266.	7.1	731
14	PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. <i>Clinical Cancer Research</i> , 2017, 23, 3711-3720.	7.0	710
15	p53 regulates epithelial \rightarrow mesenchymal transition and stem cell properties through modulating miRNAs. <i>Nature Cell Biology</i> , 2011, 13, 317-323.	10.3	674
16	Loss of FBP1 by Snail-Mediated Repression Provides Metabolic Advantages in Basal-like Breast Cancer. <i>Cancer Cell</i> , 2013, 23, 316-331.	16.8	660
17	Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. <i>Nature Communications</i> , 2016, 7, 12632.	12.8	648
18	Epidermal Growth Factor Receptor Cooperates with Signal Transducer and Activator of Transcription 3 to Induce Epithelial-Mesenchymal Transition in Cancer Cells via Up-regulation of TWIST Gene Expression. <i>Cancer Research</i> , 2007, 67, 9066-9076.	0.9	605

#	ARTICLE	IF	CITATIONS
19	Generation and characterization of androgen receptor knockout (ARKO) mice: An <i>in vivo</i> model for the study of androgen functions in selective tissues. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 13498-13503.	7.1	591
20	ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. <i>Nature Cell Biology</i> , 2008, 10, 138-148.	10.3	590
21	IKK β Suppression of TSC1 Links Inflammation and Tumor Angiogenesis via the mTOR Pathway. <i>Cell</i> , 2007, 130, 440-455.	28.9	585
22	BAP1 links metabolic regulation of ferroptosis to tumour suppression. <i>Nature Cell Biology</i> , 2018, 20, 1181-1192.	10.3	565
23	Long noncoding RNA MALAT1 suppresses breast cancer metastasis. <i>Nature Genetics</i> , 2018, 50, 1705-1715.	21.4	561
24	Deubiquitination and Stabilization of PD-L1 by CSN5. <i>Cancer Cell</i> , 2016, 30, 925-939.	16.8	538
25	The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells. <i>Cancer Research</i> , 2004, 64, 2343-2346.	0.9	535
26	Erk Associates with and Primes GSK-3 β for Its Inactivation Resulting in Upregulation of β -Catenin. <i>Molecular Cell</i> , 2005, 19, 159-170.	9.7	535
27	PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis. <i>Nature Cell Biology</i> , 2020, 22, 1264-1275.	10.3	508
28	Mechanisms Controlling PD-L1 Expression in Cancer. <i>Molecular Cell</i> , 2019, 76, 359-370.	9.7	501
29	Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. <i>Cancer Cell</i> , 2004, 6, 459-469.	16.8	497
30	Akt-Mediated Phosphorylation of EZH2 Suppresses Methylation of Lysine 27 in Histone H3. <i>Science</i> , 2005, 310, 306-310.	12.6	497
31	Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1. <i>Molecular Cell</i> , 2018, 71, 606-620.e7.	9.7	491
32	The <i>neu</i> Gene: an <i>erbB</i> B-Homologous Gene Distinct from and Unlinked to the Gene Encoding the EGF Receptor. <i>Science</i> , 1985, 229, 976-978.	12.6	490
33	Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. <i>Cancer Cell</i> , 2005, 7, 575-589.	16.8	463
34	KrasG12D-Induced IKK2 β /NF- κ B Activation by IL-1 α and p62 Feedforward Loops Is Required for Development of Pancreatic Ductal Adenocarcinoma. <i>Cancer Cell</i> , 2012, 21, 105-120.	16.8	453
35	The LINK-A lncRNA activates normoxic HIF1 α signalling in triple-negative breast cancer. <i>Nature Cell Biology</i> , 2016, 18, 213-224.	10.3	444
36	Survival of Cancer Cells Is Maintained by EGFR Independent of Its Kinase Activity. <i>Cancer Cell</i> , 2008, 13, 385-393.	16.8	432

#	ARTICLE	IF	CITATIONS
37	Epithelialâ€“Mesenchymal Transition Induced by TNF-Î± Requires NF-Î±Bâ€“Mediated Transcriptional Upregulation of Twist1. <i>Cancer Research</i> , 2012, 72, 1290-1300.	0.9	406
38	lncRNA Directs Cooperative Epigenetic Regulation Downstream of Chemokine Signals. <i>Cell</i> , 2014, 159, 1110-1125.	28.9	393
39	Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1. <i>Cancer Cell</i> , 2018, 33, 187-201.e10.	16.8	381
40	TRIM24 links a non-canonical histone signature to breast cancer. <i>Nature</i> , 2010, 468, 927-932.	27.8	374
41	EZH2 Promotes Expansion of Breast Tumor Initiating Cells through Activation of RAF1-Î²-Catenin Signaling. <i>Cancer Cell</i> , 2011, 19, 86-100.	16.8	371
42	ATM-mediated stabilization of ZEB1 promotes DNA damage response and radioresistance through CHK1. <i>Nature Cell Biology</i> , 2014, 16, 864-875.	10.3	367
43	Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. <i>Oncogene</i> , 2000, 19, 6115-6121.	5.9	363
44	LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker. <i>Nature Medicine</i> , 2012, 18, 1511-1517.	30.7	361
45	Degradation of Mcl-1 by Î²-TrCP Mediates Glycogen Synthase Kinase 3-Induced Tumor Suppression and Chemosensitization. <i>Molecular and Cellular Biology</i> , 2007, 27, 4006-4017.	2.3	348
46	Regulation of Tumor Angiogenesis by EZH2. <i>Cancer Cell</i> , 2010, 18, 185-197.	16.8	346
47	Protein localization in disease and therapy. <i>Journal of Cell Science</i> , 2011, 124, 3381-3392.	2.0	346
48	Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth. <i>Cell Research</i> , 2018, 28, 862-864.	12.0	345
49	KEAP1 E3 Ligase-Mediated Downregulation of NF-Î±B Signaling by Targeting IKKÎ². <i>Molecular Cell</i> , 2009, 36, 131-140.	9.7	344
50	Cyclin D1 Is Required for Transformation by Activated Neu and Is Induced through an E2F-Dependent Signaling Pathway. <i>Molecular and Cellular Biology</i> , 2000, 20, 672-683.	2.3	342
51	CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells. <i>Nature Cell Biology</i> , 2011, 13, 87-94.	10.3	339
52	Î²-catenin interacts with and inhibits NF-Î±B in human colon and breast cancer. <i>Cancer Cell</i> , 2002, 2, 323-334.	16.8	336
53	Overexpression of ErbB2 Blocks Taxol-Induced Apoptosis by Upregulation of p21Cip1, which Inhibits p34Cdc2 Kinase. <i>Molecular Cell</i> , 1998, 2, 581-591.	9.7	335
54	Pharmacological Inactivation of Skp2 SCF Ubiquitin Ligase Restricts Cancer Stem Cell Traits and Cancer Progression. <i>Cell</i> , 2013, 154, 556-568.	28.9	335

#	ARTICLE	IF	CITATIONS
55	Interplay among BRCA1, SIRT1, and Survivin during BRCA1-Associated Tumorigenesis. <i>Molecular Cell</i> , 2008, 32, 11-20.	9.7	334
56	Expression of Autotaxin and Lysophosphatidic Acid Receptors Increases Mammary Tumorigenesis, Invasion, and Metastases. <i>Cancer Cell</i> , 2009, 15, 539-550.	16.8	332
57	The Skp2-SCF E3 Ligase Regulates Akt Ubiquitination, Glycolysis, Herceptin Sensitivity, and Tumorigenesis. <i>Cell</i> , 2012, 149, 1098-1111.	28.9	332
58	HER-2/neu Blocks Tumor Necrosis Factor-induced Apoptosis via the Akt/NF- κ B Pathway. <i>Journal of Biological Chemistry</i> , 2000, 275, 8027-8031.	3.4	328
59	The Crosstalk of mTOR/S6K1 and Hedgehog Pathways. <i>Cancer Cell</i> , 2012, 21, 374-387.	16.8	322
60	EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2. <i>Nature</i> , 2013, 497, 383-387.	27.8	321
61	The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. <i>Cancer Cell</i> , 2006, 9, 209-223.	16.8	308
62	The role of EZH2 in tumour progression. <i>British Journal of Cancer</i> , 2012, 106, 243-247.	6.4	307
63	Targeting Mammalian Target of Rapamycin Synergistically Enhances Chemotherapy-Induced Cytotoxicity in Breast Cancer Cells. <i>Clinical Cancer Research</i> , 2004, 10, 7031-7042.	7.0	303
64	Improved peak detection and quantification of mass spectrometry data acquired from surface-enhanced laser desorption and ionization by denoising spectra with the undecimated discrete wavelet transform. <i>Proteomics</i> , 2005, 5, 4107-4117.	2.2	293
65	The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells. <i>Oncogene</i> , 1999, 18, 7034-7045.	5.9	288
66	P27kip1 Down-Regulation Is Associated with Trastuzumab Resistance in Breast Cancer Cells. <i>Cancer Research</i> , 2004, 64, 3981-3986.	0.9	283
67	STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion. <i>Nature Communications</i> , 2018, 9, 1908.	12.8	282
68	Tyrosine phosphorylation controls PCNA function through protein stability. <i>Nature Cell Biology</i> , 2006, 8, 1359-1368.	10.3	277
69	Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. <i>Nature Immunology</i> , 2019, 20, 835-851.	14.5	277
70	Determinants of Rapamycin Sensitivity in Breast Cancer Cells. <i>Clinical Cancer Research</i> , 2004, 10, 1013-1023.	7.0	269
71	Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. <i>Cancer Cell</i> , 2004, 6, 251-261.	16.8	261
72	Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival. <i>British Journal of Cancer</i> , 2006, 94, 184-188.	6.4	254

#	ARTICLE	IF	CITATIONS
73	A ROR1-HER3-lncRNA signalling axis modulates the Hippo-YAP pathway to regulate bone metastasis. <i>Nature Cell Biology</i> , 2017, 19, 106-119.	10.3	253
74	Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. <i>Molecular Carcinogenesis</i> , 2008, 47, 701-706.	2.7	249
75	Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy. <i>Nature Communications</i> , 2021, 12, 832.	12.8	248
76	Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade. <i>Gut</i> , 2019, 68, 1653-1666.	12.1	246
77	Regulation and Role of EZH2 in Cancer. <i>Cancer Research and Treatment</i> , 2014, 46, 209-222.	3.0	243
78	Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy. <i>Cancer Cell</i> , 2019, 36, 168-178.e4.	16.8	240
79	A New Fork for Clinical Application: Targeting Forkhead Transcription Factors in Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 752-757.	7.0	237
80	The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 575-588.	5.9	237
81	Systemic tumor suppression by the proapoptotic gene bik. <i>Cancer Research</i> , 2002, 62, 8-12.	0.9	236
82	A New Mutational activation in the PI3K Pathway. <i>Cancer Cell</i> , 2007, 12, 104-107.	16.8	230
83	Regulatable Expression of p21-activated Kinase-1 Promotes Anchorage-independent Growth and Abnormal Organization of Mitotic Spindles in Human Epithelial Breast Cancer Cells. <i>Journal of Biological Chemistry</i> , 2000, 275, 36238-36244.	3.4	226
84	Astrocytes Upregulate Survival Genes in Tumor Cells and Induce Protection from Chemotherapy. <i>Neoplasia</i> , 2011, 13, 286-298.	5.3	224
85	Hippo Coactivator YAP1 Upregulates SOX9 and Endows Esophageal Cancer Cells with Stem-like Properties. <i>Cancer Research</i> , 2014, 74, 4170-4182.	0.9	219
86	RAC1 activation mediates Twist1-induced cancer cell migration. <i>Nature Cell Biology</i> , 2012, 14, 366-374.	10.3	217
87	Interaction between the Adhesion Receptor, CD44, and the Oncogene Product, p185, Promotes Human Ovarian Tumor Cell Activation. <i>Journal of Biological Chemistry</i> , 1997, 272, 27913-27918.	3.4	215
88	Endosomal Transport of ErbB-2: Mechanism for Nuclear Entry of the Cell Surface Receptor. <i>Molecular and Cellular Biology</i> , 2005, 25, 11005-11018.	2.3	214
89	Phosphorylation of CBP by IKK β Promotes Cell Growth by Switching the Binding Preference of CBP from p53 to NF- κ B. <i>Molecular Cell</i> , 2007, 26, 75-87.	9.7	212
90	Physiological regulation of Akt activity and stability. <i>American Journal of Translational Research (discontinued)</i> , 2010, 2, 19-42.	0.0	212

#	ARTICLE	IF	CITATIONS
91	The role of the VEGF-C/VEGFR-3 axis in cancer progression. <i>British Journal of Cancer</i> , 2007, 96, 541-545.	6.4	211
92	Nuclear-cytoplasmic transport of EGFR involves receptor endocytosis, importin β 1 and CRM1. <i>Journal of Cellular Biochemistry</i> , 2006, 98, 1570-1583.	2.6	210
93	EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocation. <i>Breast Cancer Research and Treatment</i> , 2006, 95, 211-218.	2.5	209
94	IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. <i>Journal of Clinical Investigation</i> , 2019, 129, 3324-3338.	8.2	209
95	Characterization of a Novel Tripartite Nuclear Localization Sequence in the EGFR Family. <i>Journal of Biological Chemistry</i> , 2007, 282, 10432-10440.	3.4	208
96	Cationic Liposome-Mediated Gene Transfer to Human Breast and Ovarian Cancer Cells and Its Biologic Effects: A Phase I Clinical Trial. <i>Journal of Clinical Oncology</i> , 2001, 19, 3422-3433.	1.6	207
97	Quality Control and Peak Finding for Proteomics Data Collected from Nipple Aspirate Fluid by Surface-Enhanced Laser Desorption and Ionization. <i>Clinical Chemistry</i> , 2003, 49, 1615-1623.	3.2	203
98	The LINK-A lncRNA interacts with PtdIns(3,4,5)P3 to hyperactivate AKT and confer resistance to AKT inhibitors. <i>Nature Cell Biology</i> , 2017, 19, 238-251.	10.3	201
99	The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines. <i>Breast Cancer: Basic and Clinical Research</i> , 2010, 4, 117822341000400.	1.1	199
100	Nuclear trafficking of the epidermal growth factor receptor family membrane proteins. <i>Oncogene</i> , 2010, 29, 3997-4006.	5.9	199
101	The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2580-2590.	7.0	199
102	Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. <i>Cancer Research</i> , 2005, 65, 338-48.	0.9	199
103	Gain-of-Function Mutant p53 Promotes Cell Growth and Cancer Cell Metabolism via Inhibition of AMPK Activation. <i>Molecular Cell</i> , 2014, 54, 960-974.	9.7	196
104	14-3-3 σ Cooperates with ErbB2 to Promote Ductal Carcinoma In Situ Progression to Invasive Breast Cancer by Inducing Epithelial-Mesenchymal Transition. <i>Cancer Cell</i> , 2009, 16, 195-207.	16.8	195
105	Vimentin is a novel AKT1 target mediating motility and invasion. <i>Oncogene</i> , 2011, 30, 457-470.	5.9	195
106	Crosstalk between Arg ¹¹⁷⁵ methylation and Tyr ¹¹⁷³ phosphorylation negatively modulates EGFR-mediated ERK activation. <i>Nature Cell Biology</i> , 2011, 13, 174-181.	10.3	192
107	Modeling Familial Cancer with Induced Pluripotent Stem Cells. <i>Cell</i> , 2015, 161, 240-254.	28.9	191
108	Deciphering the transcriptional complex critical for RhoA gene expression and cancer metastasis. <i>Nature Cell Biology</i> , 2010, 12, 457-467.	10.3	190

#	ARTICLE	IF	CITATIONS
109	EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape. <i>Cancer Research</i> , 2016, 76, 1284-1296.	0.9	190
110	Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. <i>Nature Medicine</i> , 2016, 22, 194-201.	30.7	189
111	Mesenchymal stem cells promote growth and angiogenesis of tumors in mice. <i>Oncogene</i> , 2013, 32, 4343-4354.	5.9	187
112	Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelial-mesenchymal transition. <i>Oncogene</i> , 2007, 26, 7859-7871.	5.9	183
113	Posttranslational Modifications of PD-L1 and Their Applications in Cancer Therapy. <i>Cancer Research</i> , 2018, 78, 6349-6353.	0.9	183
114	Crystal structure of the human FOXO3a-DBD/DNA complex suggests the effects of post-translational modification. <i>Nucleic Acids Research</i> , 2007, 35, 6984-6994.	14.5	178
115	JAK2-binding long noncoding RNA promotes breast cancer brain metastasis. <i>Journal of Clinical Investigation</i> , 2017, 127, 4498-4515.	8.2	177
116	MDM2 Promotes Cell Motility and Invasiveness by Regulating E-Cadherin Degradation. <i>Molecular and Cellular Biology</i> , 2006, 26, 7269-7282.	2.3	176
117	Kruppel-Like Factor 8 Induces Epithelial to Mesenchymal Transition and Epithelial Cell Invasion. <i>Cancer Research</i> , 2007, 67, 7184-7193.	0.9	175
118	14-3-3 Overexpression Defines High Risk for Breast Cancer Recurrence and Promotes Cancer Cell Survival. <i>Cancer Research</i> , 2009, 69, 3425-3432.	0.9	175
119	Deubiquitylation and stabilization of PTEN by USP13. <i>Nature Cell Biology</i> , 2013, 15, 1486-1494.	10.3	172
120	Myeloid Cell Leukemia-1 Inversely Correlates with Glycogen Synthase Kinase-3 Activity and Associates with Poor Prognosis in Human Breast Cancer. <i>Cancer Research</i> , 2007, 67, 4564-4571.	0.9	171
121	The gluconeogenic enzyme PCK1 phosphorylates INSIG1/2 for lipogenesis. <i>Nature</i> , 2020, 580, 530-535.	27.8	171
122	Independent control elements that determine yolk protein gene expression in alternative <i>Drosophila</i> tissues.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1985, 82, 1396-1400.	7.1	168
123	Hyaluronan Promotes CD44v3-Vav2 Interaction with Grb2-p185HER2 and Induces Rac1 and Ras Signaling during Ovarian Tumor Cell Migration and Growth. <i>Journal of Biological Chemistry</i> , 2001, 276, 48679-48692.	3.4	168
124	Down-regulation of Myeloid Cell Leukemia-1 through Inhibiting Erk/Pin 1 Pathway by Sorafenib Facilitates Chemosensitization in Breast Cancer. <i>Cancer Research</i> , 2008, 68, 6109-6117.	0.9	167
125	Vimentin Is a Novel Anti-Cancer Therapeutic Target; Insights from In Vitro and In Vivo Mice Xenograft Studies. <i>PLoS ONE</i> , 2010, 5, e10105.	2.5	166
126	Galectin-3 Mediates Nuclear β -Catenin Accumulation and Wnt Signaling in Human Colon Cancer Cells by Regulation of Glycogen Synthase Kinase-3 Activity. <i>Cancer Research</i> , 2009, 69, 1343-1349.	0.9	165

#	ARTICLE	IF	CITATIONS
127	KDM2A promotes lung tumorigenesis by epigenetically enhancing ERK1/2 signaling. <i>Journal of Clinical Investigation</i> , 2013, 123, 5231-5246.	8.2	164
128	14-3-3 η Turns TGF- β 's Function from Tumor Suppressor to Metastasis Promoter in Breast Cancer by Contextual Changes of Smad Partners from p53 to Gli2. <i>Cancer Cell</i> , 2015, 27, 177-192.	16.8	158
129	Palmitoylation stabilizes PD-L1 to promote breast tumor growth. <i>Cell Research</i> , 2019, 29, 83-86.	12.0	158
130	Co-regulation of β -Myb expression by E2F1 and EGF receptor. <i>Molecular Carcinogenesis</i> , 2006, 45, 10-17.	2.7	157
131	Nuclear Translocation of the Epidermal Growth Factor Receptor Family Membrane Tyrosine Kinase Receptors. <i>Clinical Cancer Research</i> , 2009, 15, 6484-6489.	7.0	157
132	Xenoestrogen-Induced Regulation of EZH2 and Histone Methylation via Estrogen Receptor Signaling to PI3K/AKT. <i>Molecular Endocrinology</i> , 2010, 24, 993-1006.	3.7	156
133	Molecular cloning of the neu gene: absence of gross structural alteration in oncogenic alleles.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1986, 83, 261-264.	7.1	155
134	Emodin Down-Regulates Androgen Receptor and Inhibits Prostate Cancer Cell Growth. <i>Cancer Research</i> , 2005, 65, 2287-2295.	0.9	155
135	Sustained activation of SMAD3/SMAD4 by FOXM1 promotes TGF- β ' dependent cancer metastasis. <i>Journal of Clinical Investigation</i> , 2014, 124, 564-579.	8.2	155
136	Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 287-305.	27.6	155
137	The Ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis. <i>Nature Medicine</i> , 2000, 6, 189-195.	30.7	154
138	Genetic Variations in the PI3K/PTEN/AKT/mTOR Pathway Are Associated With Clinical Outcomes in Esophageal Cancer Patients Treated With Chemoradiotherapy. <i>Journal of Clinical Oncology</i> , 2009, 27, 857-871.	1.6	154
139	Mesenchymal Stem Cells Promote Formation of Colorectal Tumors in Mice. <i>Gastroenterology</i> , 2011, 141, 1046-1056.	1.3	154
140	Nuclear Translocation of Epidermal Growth Factor Receptor by Akt-dependent Phosphorylation Enhances Breast Cancer-resistant Protein Expression in Gefitinib-resistant Cells. <i>Journal of Biological Chemistry</i> , 2011, 286, 20558-20568.	3.4	154
141	GSK-3 β Targets Cdc25A for Ubiquitin-Mediated Proteolysis, and GSK-3 β Inactivation Correlates with Cdc25A Overproduction in Human Cancers. <i>Cancer Cell</i> , 2008, 13, 36-47.	16.8	151
142	Phosphorylation/Cytoplasmic Localization of p21Cip1/WAF1 Is Associated with HER2/neu Overexpression and Provides a Novel Combination Predictor for Poor Prognosis in Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2004, 10, 3815-3824.	7.0	150
143	Molecular predictors of response to trastuzumab and lapatinib in breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 98-107.	27.6	148
144	Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1990, 87, 4499-4503.	7.1	142

#	ARTICLE	IF	CITATIONS
145	Regulation of Embryonic and Induced Pluripotency by Aurora Kinase-p53 Signaling. <i>Cell Stem Cell</i> , 2012, 11, 179-194.	11.1	142
146	Nuclear AURKA acquires kinase-independent transactivating function to enhance breast cancer stem cell phenotype. <i>Nature Communications</i> , 2016, 7, 10180.	12.8	142
147	Long non-coding RNAs: versatile master regulators of gene expression and crucial players in cancer. <i>American Journal of Translational Research (discontinued)</i> , 2012, 4, 127-50.	0.0	141
148	Cytokine Receptor CXCR4 Mediates Estrogen-Independent Tumorigenesis, Metastasis, and Resistance to Endocrine Therapy in Human Breast Cancer. <i>Cancer Research</i> , 2011, 71, 603-613.	0.9	140
149	Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function. <i>Molecular Cell</i> , 2018, 69, 279-291.e5.	9.7	138
150	High tumoral maspin expression is associated with improved survival of patients with oral squamous cell carcinoma. <i>Oncogene</i> , 2000, 19, 2398-2403.	5.9	137
151	TYRO3 induces anti-“PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	135
152	Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer. <i>Molecular Carcinogenesis</i> , 2009, 48, 610-617.	2.7	131
153	MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1. <i>Gastroenterology</i> , 2019, 156, 1849-1861.e13.	1.3	131
154	AIM2 suppresses human breast cancer cell proliferation in vitro and mammary tumor growth in a mouse model. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 1-7.	4.1	129
155	Recombinant Human Erythropoietin Antagonizes Trastuzumab Treatment of Breast Cancer Cells via Jak2-Mediated Src Activation and PTEN Inactivation. <i>Cancer Cell</i> , 2010, 18, 423-435.	16.8	129
156	Nuclear functions and subcellular trafficking mechanisms of the epidermal growth factor receptor family. <i>Cell and Bioscience</i> , 2012, 2, 13.	4.8	128
157	Dysregulation of MicroRNAs in cancer. <i>Journal of Biomedical Science</i> , 2012, 19, 90.	7.0	127
158	Molecular mechanisms and functions of pyroptosis in inflammation and antitumor immunity. <i>Molecular Cell</i> , 2021, 81, 4579-4590.	9.7	127
159	ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis. <i>Cancer Cell</i> , 2020, 37, 324-339.e8.	16.8	126
160	A novel splice variant ofHER2 with increased transformation activity. <i>Molecular Carcinogenesis</i> , 1998, 23, 62-68.	2.7	125
161	ERK Activation Globally Downregulates miRNAs through Phosphorylating Exportin-5. <i>Cancer Cell</i> , 2016, 30, 723-736.	16.8	125
162	The Adaptor Protein CARD9 Protects against Colon Cancer by Restricting Mycobiota-Mediated Expansion of Myeloid-Derived Suppressor Cells. <i>Immunity</i> , 2018, 49, 504-514.e4.	14.3	125

#	ARTICLE	IF	CITATIONS
163	Modulation of Redox Homeostasis by Inhibition of MTHFD2 in Colorectal Cancer: Mechanisms and Therapeutic Implications. <i>Journal of the National Cancer Institute</i> , 2019, 111, 584-596.	6.3	125
164	Phosphorylation on Tyrosine-15 of p34Cdc2 by ErbB2 Inhibits p34Cdc2 Activation and Is Involved in Resistance to Taxol-Induced Apoptosis. <i>Molecular Cell</i> , 2002, 9, 993-1004.	9.7	124
165	FOXC1 Activates Smoothed-Independent Hedgehog Signaling in Basal-like Breast Cancer. <i>Cell Reports</i> , 2015, 13, 1046-1058.	6.4	124
166	Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol. <i>Oncogene</i> , 1998, 16, 2087-2094.	5.9	122
167	Block-Cell-Printing for live single-cell printing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 2948-2953.	7.1	122
168	Linking genomic reorganization to tumor initiation via the giant cell cycle. <i>Oncogenesis</i> , 2016, 5, e281-e281.	4.9	121
169	A perspective on anti-EGFR therapies targeting triple-negative breast cancer. <i>American Journal of Cancer Research</i> , 2016, 6, 1609-23.	1.4	121
170	Nuclear Localization of P185neu Tyrosine Kinase and Its Association with Transcriptional Transactivation. <i>Biochemical and Biophysical Research Communications</i> , 1994, 203, 1589-1598.	2.1	119
171	Novel targets of Akt, p21, and MDM2. <i>Seminars in Oncology</i> , 2002, 29, 62-70.	2.2	119
172	APOBEC3G promotes liver metastasis in an orthotopic mouse model of colorectal cancer and predicts human hepatic metastasis. <i>Journal of Clinical Investigation</i> , 2011, 121, 4526-4536.	8.2	117
173	Sequence and structure conservation in yolk proteins and their genes. <i>Journal of Molecular Biology</i> , 1983, 164, 481-492.	4.2	116
174	Induction of Akt Activity by Chemotherapy Confers Acquired Resistance. <i>Journal of the Formosan Medical Association</i> , 2009, 108, 180-194.	1.7	116
175	COPI-mediated retrograde trafficking from the Golgi to the ER regulates EGFR nuclear transport. <i>Biochemical and Biophysical Research Communications</i> , 2010, 399, 498-504.	2.1	116
176	MiR-520h-mediated FOXC2 regulation is critical for inhibition of lung cancer progression by resveratrol. <i>Oncogene</i> , 2013, 32, 431-443.	5.9	116
177	Overexpression of the c-erbB-2/neu-encoded p185 protein in primary lung cancer. <i>Molecular Carcinogenesis</i> , 1992, 5, 213-218.	2.7	114
178	Advances in Targeting Human Epidermal Growth Factor Receptor-2 Signaling for Cancer Therapy: Fig. 1.. <i>Clinical Cancer Research</i> , 2006, 12, 6326-6330.	7.0	114
179	PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response. <i>Journal of Clinical Investigation</i> , 2015, 125, 4529-4543.	8.2	114
180	Expression profile of tyrosine kinases in breast cancer. <i>Clinical Cancer Research</i> , 2002, 8, 361-7.	7.0	114

#	ARTICLE	IF	CITATIONS
181	Oncogenic Signals of HER-2/neu in Regulating the Stability of the Cyclin-dependent Kinase Inhibitor p27. <i>Journal of Biological Chemistry</i> , 2000, 275, 24735-24739.	3.4	113
182	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Reverses Mesenchymal to Epithelial Phenotype and Inhibits Metastasis in Inflammatory Breast Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 6639-6648.	7.0	113
183	p53 Acetylation Is Crucial for Its Transcription-independent Proapoptotic Functions. <i>Journal of Biological Chemistry</i> , 2009, 284, 11171-11183.	3.4	111
184	Cancer-specific activation of the survivin promoter and its potential use in gene therapy. <i>Cancer Gene Therapy</i> , 2004, 11, 740-747.	4.6	110
185	Wnt, Hedgehog, and Snail: Sister Pathways That Control by GSK-3beta and beta-Trcp in the Regulation of Metastasis. <i>Cell Cycle</i> , 2005, 4, 772-776.	2.6	110
186	miR-100 Induces Epithelial-Mesenchymal Transition but Suppresses Tumorigenesis, Migration and Invasion. <i>PLoS Genetics</i> , 2014, 10, e1004177.	3.5	110
187	Targeting YB-1 in HER-2 Overexpressing Breast Cancer Cells Induces Apoptosis via the mTOR/STAT3 Pathway and Suppresses Tumor Growth in Mice. <i>Cancer Research</i> , 2008, 68, 8661-8666.	0.9	109
188	Human pro-Tumor Necrosis Factor Is a Homotrimer. <i>Biochemistry</i> , 1996, 35, 8216-8225.	2.5	108
189	Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neu-induced cellular transformation and metastasis-associated properties. <i>Oncogene</i> , 1998, 16, 2855-2863.	5.9	108
190	Actin cytoskeleton remodeling drives epithelial-mesenchymal transition for hepatoma invasion and metastasis in mice. <i>Hepatology</i> , 2018, 67, 2226-2243.	7.3	108
191	The Translocon Sec61 ^β Localized in the Inner Nuclear Membrane Transports Membrane-embedded EGF Receptor to the Nucleus. <i>Journal of Biological Chemistry</i> , 2010, 285, 38720-38729.	3.4	107
192	Interplay between arginine methylation and ubiquitylation regulates KLF4-mediated genome stability and carcinogenesis. <i>Nature Communications</i> , 2015, 6, 8419.	12.8	107
193	Role of erbB2 in breast cancer chemosensitivity. <i>BioEssays</i> , 2000, 22, 673-680.	2.5	106
194	Dysregulation of cellular signaling by HER2 in breast cancer. <i>Seminars in Oncology</i> , 2003, 30, 38-48.	2.2	106
195	Aurora Kinase A Promotes Ovarian Tumorigenesis through Dysregulation of the Cell Cycle and Suppression of BRCA2. <i>Clinical Cancer Research</i> , 2010, 16, 3171-3181.	7.0	106
196	Inhibition of Nuclear Factor- κ B Activity Is Involved in E1A-mediated Sensitization of Radiation-induced Apoptosis. <i>Journal of Biological Chemistry</i> , 1997, 272, 32739-32742.	3.4	105
197	Amplification and expression of the <i>erbB2/neu</i> proto-oncogene in human bladder cancer. <i>Molecular Carcinogenesis</i> , 1990, 3, 254-257.	2.7	104
198	All Roads Lead to mTOR: Integrating Inflammation and Tumor Angiogenesis. <i>Cell Cycle</i> , 2007, 6, 3011-3014.	2.6	104

#	ARTICLE	IF	CITATIONS
199	Targeting HER2: Recent developments and future directions for breast cancer patients. <i>Seminars in Oncology</i> , 2001, 28, 21-29.	2.2	104
200	Advances in Targeting IKK and IKK-Related Kinases for Cancer Therapy. <i>Clinical Cancer Research</i> , 2008, 14, 5656-5662.	7.0	102
201	Regulation of the Activity of p38 Mitogen-Activated Protein Kinase by Akt in Cancer and Adenoviral Protein E1A-Mediated Sensitization to Apoptosis. <i>Molecular and Cellular Biology</i> , 2003, 23, 6836-6848.	2.3	101
202	A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. <i>Nature Communications</i> , 2016, 7, 11169.	12.8	100
203	Signaling cross-talk in the resistance to HER family receptor targeted therapy. <i>Oncogene</i> , 2014, 33, 1073-1081.	5.9	99
204	JARID1D Is a Suppressor and Prognostic Marker of Prostate Cancer Invasion and Metastasis. <i>Cancer Research</i> , 2016, 76, 831-843.	0.9	99
205	MicroRNA-205 signaling regulates mammary stem cell fate and tumorigenesis. <i>Journal of Clinical Investigation</i> , 2014, 124, 3093-3106.	8.2	99
206	Preferential DNA Damage and Poor Repair Determine ras Gene Mutational Hotspot in Human Cancer. <i>Journal of the National Cancer Institute</i> , 2002, 94, 1527-1536.	6.3	98
207	Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry. <i>Breast Cancer Research and Treatment</i> , 2005, 89, 149-157.	2.5	98
208	Role of Glycogen Synthase Kinase 3 β in Rapamycin-Mediated Cell Cycle Regulation and Chemosensitivity. <i>Cancer Research</i> , 2005, 65, 1961-1972.	0.9	98
209	A UBE2O-AMPK α 2 Axis that Promotes Tumor Initiation and Progression Offers Opportunities for Therapy. <i>Cancer Cell</i> , 2017, 31, 208-224.	16.8	98
210	Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells. <i>Breast Cancer Research</i> , 2010, 12, R96.	5.0	97
211	Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade. <i>Molecular Cell</i> , 2021, 81, 2317-2331.e6.	9.7	97
212	Enhanced Chemoresistance by Elevation of p185neu Levels in HER-2/neu-Transfected Human Lung Cancer Cells. <i>Journal of the National Cancer Institute</i> , 1995, 87, 682-684.	6.3	96
213	A Hypoxia-Independent Hypoxia-Inducible Factor-1 Activation Pathway Induced by Phosphatidylinositol-3 Kinase/Akt in HER2 Overexpressing Cells. <i>Cancer Research</i> , 2005, 65, 3257-3263.	0.9	96
214	Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β -blockers. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	96
215	RNA helicase A is a DNA-binding partner for EGFR-mediated transcriptional activation in the nucleus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 16125-16130.	7.1	95
216	Suppression of tumorigenicity of breast cancer cells by an epithelial cell adhesion molecule (C-CAM1): the adhesion and growth suppression are mediated by different domains. <i>Oncogene</i> , 1997, 14, 1697-1704.	5.9	94

#	ARTICLE	IF	CITATIONS
217	Smurf2-mediated degradation of EZH2 enhances neuron differentiation and improves functional recovery after ischaemic stroke. <i>EMBO Molecular Medicine</i> , 2013, 5, 531-547.	6.9	94
218	Erythropoietin Stimulates Tumor Growth via EphB4. <i>Cancer Cell</i> , 2015, 28, 610-622.	16.8	94
219	Breast cancer brain metastases. <i>Cancer and Metastasis Reviews</i> , 2007, 26, 635-643.	5.9	93
220	Caspase-Independent Cell Death Is Involved in the Negative Effect of EGF Receptor Inhibitors on Cisplatin in Non-Small Cell Lung Cancer Cells. <i>Clinical Cancer Research</i> , 2013, 19, 845-854.	7.0	93
221	Recombinant PML adenovirus suppresses growth and tumorigenicity of human breast cancer cells by inducing G1 cell cycle arrest and apoptosis. <i>Oncogene</i> , 1998, 16, 1839-1849.	5.9	92
222	Development and validation of a radiopathomics model to predict pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a multicentre observational study. <i>The Lancet Digital Health</i> , 2022, 4, e8-e17.	12.3	91
223	Adenovirus type 5 E1A gene products act as transformation suppressors of the neu oncogene.. <i>Molecular and Cellular Biology</i> , 1991, 11, 1745-1750.	2.3	90
224	Beyond NF- κ B activation: nuclear functions of κ B kinase $\hat{\pm}$. <i>Journal of Biomedical Science</i> , 2013, 20, 3.	7.0	90
225	MDM2-mediated degradation of SIRT6 phosphorylated by AKT1 promotes tumorigenesis and trastuzumab resistance in breast cancer. <i>Science Signaling</i> , 2014, 7, ra71.	3.6	90
226	TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer. <i>Modern Pathology</i> , 2021, 34, 710-719.	5.5	90
227	E1A Sensitizes Cells to Tumor Necrosis Factor-induced Apoptosis through Inhibition of κ B Kinases and Nuclear Factor κ B Activities. <i>Journal of Biological Chemistry</i> , 1999, 274, 21495-21498.	3.4	89
228	JNK1 negatively controls antifungal innate immunity by suppressing CD23 expression. <i>Nature Medicine</i> , 2017, 23, 337-346.	30.7	89
229	The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis. <i>Journal of Biomedical Science</i> , 2020, 27, 77.	7.0	89
230	Targeting Glycosylated PD-1 Induces Potent Antitumor Immunity. <i>Cancer Research</i> , 2020, 80, 2298-2310.	0.9	87
231	Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. <i>Oncogene</i> , 1997, 15, 953-960.	5.9	86
232	Targeted Expression of miR-34a Using the T-VISA System Suppresses Breast Cancer Cell Growth and Invasion. <i>Molecular Therapy</i> , 2012, 20, 2326-2334.	8.2	85
233	Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells. <i>Cancer Research</i> , 2002, 62, 5703-10.	0.9	85
234	Crossregulation of NF- κ B by the APC/GSK-3 β -catenin pathway. <i>Molecular Carcinogenesis</i> , 2004, 39, 139-146.	2.7	84

#	ARTICLE	IF	CITATIONS
235	CARMA3 is Crucial for EGFR-Induced Activation of NF- κ B and Tumor Progression. <i>Cancer Research</i> , 2011, 71, 2183-2192.	0.9	83
236	IKK α Activation of NOTCH Links Tumorigenesis via FOXA2 Suppression. <i>Molecular Cell</i> , 2012, 45, 171-184.	9.7	83
237	Epigenetic Regulation of the miR142-3p/Interleukin-6 Circuit in Glioblastoma. <i>Molecular Cell</i> , 2013, 52, 693-706.	9.7	83
238	A hypoxia-responsive TRAF6-ATM-H2AX signalling axis promotes HIF1 α activation, tumorigenesis and metastasis. <i>Nature Cell Biology</i> , 2017, 19, 38-51.	10.3	83
239	Stabilization of ERK-Phosphorylated METTL3 by USP5 Increases m6A Methylation. <i>Molecular Cell</i> , 2020, 80, 633-647.e7.	9.7	83
240	Targeting ECM-Integrin Interaction with Liposome-Encapsulated Small Interfering RNAs Inhibits the Growth of Human Prostate Cancer in a Bone Xenograft Imaging Model. <i>Molecular Therapy</i> , 2005, 12, 634-643.	8.2	82
241	ARD1 Stabilization of TSC2 Suppresses Tumorigenesis Through the mTOR Signaling Pathway. <i>Science Signaling</i> , 2010, 3, ra9.	3.6	82
242	The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer. <i>Oncogene</i> , 1997, 14, 561-568.	5.9	81
243	Deep and high-resolution three-dimensional tracking of single particles using nonlinear and multiplexed illumination. <i>Nature Communications</i> , 2015, 6, 7874.	12.8	81
244	HER-2/neu Oncogene Characterization in Head and Neck Squamous Cell Carcinoma. <i>JAMA Otolaryngology</i> , 1995, 121, 1265-1270.	1.2	79
245	EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer. <i>Oncogene</i> , 2018, 37, 208-217.	5.9	79
246	Strategies to target HER2/neu overexpression for cancer therapy. <i>Drug Resistance Updates</i> , 2003, 6, 129-136.	14.4	78
247	Peptidyl-prolyl cis/trans isomerase Pin1 is critical for the regulation of PKB/Akt stability and activation phosphorylation. <i>Oncogene</i> , 2009, 28, 2436-2445.	5.9	78
248	Elevated BCRP/ABCG2 Expression Confers Acquired Resistance to Gefitinib in Wild-Type EGFR-Expressing Cells. <i>PLoS ONE</i> , 2011, 6, e21428.	2.5	77
249	Unfolded Protein Response Is Required in nu/nu Mice Microvasculature for Treating Breast Tumor with Tunicamycin. <i>Journal of Biological Chemistry</i> , 2011, 286, 29127-29138.	3.4	77
250	Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma. <i>Nature Communications</i> , 2017, 8, 14437.	12.8	77
251	Akt is required for Axl-Gas6 signaling to protect cells from E1A-mediated apoptosis. <i>Oncogene</i> , 2002, 21, 329-336.	5.9	76
252	Selective small molecule PARG inhibitor causes replication fork stalling and cancer cell death. <i>Nature Communications</i> , 2019, 10, 5654.	12.8	75

#	ARTICLE	IF	CITATIONS
253	Aberrant expression of the c-erbB-2/neu protooncogene in ovarian cancer. <i>Cancer Letters</i> , 1992, 61, 95-103.	7.2	74
254	STK15/Aurora-A expression in primary breast tumors is correlated with nuclear grade but not with prognosis. <i>Cancer</i> , 2004, 100, 12-19.	4.1	74
255	Targeting Tyrosine Phosphorylation of PCNA Inhibits Prostate Cancer Growth. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 29-36.	4.1	73
256	Proteolytic cleavage, trafficking, and functions of nuclear receptor tyrosine kinases. <i>FEBS Journal</i> , 2015, 282, 3693-3721.	4.7	73
257	Membrane-bound Trafficking Regulates Nuclear Transport of Integral Epidermal Growth Factor Receptor (EGFR) and ErbB-2. <i>Journal of Biological Chemistry</i> , 2012, 287, 16869-16879.	3.4	72
258	High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma. <i>Oncogene</i> , 2016, 35, 1565-1574.	5.9	72
259	Targeted Expression of BikDD Eradicates Pancreatic Tumors in Noninvasive Imaging Models. <i>Cancer Cell</i> , 2007, 12, 52-65.	16.8	71
260	The sequence of the <i>Drosophila melanogaster</i> gene for yolk protein 1. <i>Nucleic Acids Research</i> , 1981, 9, 6407-6419.	14.5	70
261	Activation of FOXO3a Is Sufficient to Reverse Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor Chemoresistance in Human Cancer. <i>Cancer Research</i> , 2010, 70, 4709-4718.	0.9	70
262	Deciphering the Role of Forkhead Transcription Factors in Cancer Therapy. <i>Current Drug Targets</i> , 2011, 12, 1284-1290.	2.1	70
263	TIG1 Promotes the Development and Progression of Inflammatory Breast Cancer through Activation of Axl Kinase. <i>Cancer Research</i> , 2013, 73, 6516-6525.	0.9	70
264	A Tumorigenic Factor Interactome Connected through Tumor Suppressor MicroRNA-198 in Human Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 5901-5913.	7.0	70
265	ADAM9 Promotes Lung Cancer Metastases to Brain by a Plasminogen Activator-Based Pathway. <i>Cancer Research</i> , 2014, 74, 5229-5243.	0.9	70
266	Crosstalk between Protease-activated Receptor 1 and Platelet-activating Factor Receptor Regulates Melanoma Cell Adhesion Molecule (MCAM/MUC18) Expression and Melanoma Metastasis. <i>Journal of Biological Chemistry</i> , 2009, 284, 28845-28855.	3.4	69
267	Structural and Functional Impacts of ER Coactivator Sequential Recruitment. <i>Molecular Cell</i> , 2017, 67, 733-743.e4.	9.7	69
268	Synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest in HER2-overexpressing breast cancer cells. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 317-328.	4.1	68
269	Blockade of Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase and Murine Double Minute Synergistically Induces Apoptosis in Acute Myeloid Leukemia via BH3-Only Proteins Puma and Bim. <i>Cancer Research</i> , 2010, 70, 2424-2434.	0.9	68
270	Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer. <i>Oncogene</i> , 2021, 40, 4992-5001.	5.9	68

#	ARTICLE	IF	CITATIONS
271	PTEN-induced partial epithelial-mesenchymal transition drives diabetic kidney disease. <i>Journal of Clinical Investigation</i> , 2019, 129, 1129-1151.	8.2	68
272	HER-2/neu-targeting gene therapy-a review. <i>Gene</i> , 1995, 159, 65-71.	2.2	67
273	A multicenter phase II study of tgDCC-E1A for the intratumoral treatment of patients with recurrent head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2002, 24, 661-669.	2.0	67
274	BikDD Eliminates Breast Cancer Initiating Cells and Synergizes with Lapatinib for Breast Cancer Treatment. <i>Cancer Cell</i> , 2011, 20, 341-356.	16.8	67
275	EGFR Modulates DNA Synthesis and Repair through Tyr Phosphorylation of Histone H4. <i>Developmental Cell</i> , 2014, 30, 224-237.	7.0	67
276	IKK α restoration via EZH2 suppression induces nasopharyngeal carcinoma differentiation. <i>Nature Communications</i> , 2014, 5, 3661.	12.8	67
277	Oral cancer progression and c-erbB-2/neu proto-oncogene expression. <i>Cancer Letters</i> , 1992, 65, 215-220.	7.2	66
278	IKK β suppression of TSC1 function links the mTOR pathway with insulin resistance. <i>International Journal of Molecular Medicine</i> , 1998, 22, 633-8.	4.0	66
279	Pharmacologic Suppression of B7-H4 Glycosylation Restores Antitumor Immunity in Immune-Cold Breast Cancers. <i>Cancer Discovery</i> , 2020, 10, 1872-1893.	9.4	66
280	Nuclear EGFR is required for cisplatin resistance and DNA repair. <i>American Journal of Translational Research (discontinued)</i> , 2009, 1, 249-58.	0.0	66
281	Her2/neu induces all-transretinoic acid (ATRA) resistance in breast cancer cells. <i>Oncogene</i> , 2002, 21, 5224-5232.	5.9	65
282	AKT1 Inhibits Epithelial-to-Mesenchymal Transition in Breast Cancer through Phosphorylation-Dependent Twist1 Degradation. <i>Cancer Research</i> , 2016, 76, 1451-1462.	0.9	65
283	Adenovirus 5 E1A-mediated tumor suppression associated with E1A-mediated apoptosis in vivo. <i>Oncogene</i> , 1998, 17, 2167-2175.	5.9	64
284	NF- κ B signaling mediates the induction of MTA1 by hepatitis B virus transactivator protein HBx. <i>Oncogene</i> , 2010, 29, 1179-1189.	5.9	64
285	Antitumor Agents. 272. Structure-Activity Relationships and In Vivo Selective Anti-Breast Cancer Activity of Novel Neo-tanshinlactone Analogues. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 2299-2308.	6.4	64
286	CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer. <i>Nature Communications</i> , 2019, 10, 5114.	12.8	64
287	Blocking immunosuppressive neutrophils deters pY696-EZH2-driven brain metastases. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	64
288	External control of Her2 expression and cancer cell growth by targeting a Ras-linked coactivator. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 12747-12752.	7.1	63

#	ARTICLE	IF	CITATIONS
289	Nuclear ErbB2 Enhances Translation and Cell Growth by Activating Transcription of Ribosomal RNA Genes. <i>Cancer Research</i> , 2011, 71, 4269-4279.	0.9	63
290	c-myc reverses neu-induced transformed morphology by transcriptional repression.. <i>Molecular and Cellular Biology</i> , 1991, 11, 354-362.	2.3	62
291	Growth inhibition of breast cancer cells by Grb2 downregulation is correlated with inactivation of mitogen-activated protein kinase in EGFR, but not in ErbB2, cells. <i>Oncogene</i> , 1999, 18, 1325-1332.	5.9	62
292	The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers. <i>Endocrine-Related Cancer</i> , 2005, 12, 511-532.	3.1	62
293	The roles of EZH2 in cell lineage commitment. <i>American Journal of Translational Research (discontinued)</i> , 2011, 3, 243-50.	0.0	62
294	Axl-Gas6 Interaction Counteracts E1A-Mediated Cell Growth Suppression and Proapoptotic Activity. <i>Molecular and Cellular Biology</i> , 1999, 19, 8075-8082.	2.3	61
295	EZH2 Regulates Neuronal Differentiation of Mesenchymal Stem Cells through PIP5K1C-dependent Calcium Signaling. <i>Journal of Biological Chemistry</i> , 2011, 286, 9657-9667.	3.4	61
296	Survival of Cancer Stem Cells under Hypoxia and Serum Depletion via Decrease in PP2A Activity and Activation of p38-MAPKAPK2-Hsp27. <i>PLoS ONE</i> , 2012, 7, e49605.	2.5	61
297	Definition of PKC- ζ , CDK6, and MET as Therapeutic Targets in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2014, 74, 4822-4835.	0.9	61
298	Deacetylation of HSPA5 by HDAC6 leads to GP78-mediated HSPA5 ubiquitination at K447 and suppresses metastasis of breast cancer. <i>Oncogene</i> , 2016, 35, 1517-1528.	5.9	61
299	Tankyrase disrupts metabolic homeostasis and promotes tumorigenesis by inhibiting LKB1-AMPK signalling. <i>Nature Communications</i> , 2019, 10, 4363.	12.8	61
300	SLFN11 inhibits hepatocellular carcinoma tumorigenesis and metastasis by targeting RPS4X via mTOR pathway. <i>Theranostics</i> , 2020, 10, 4627-4643.	10.0	61
301	Cancer-specific Gene Therapy. <i>Advances in Genetics</i> , 2005, 54, 233-255.	1.8	59
302	CXCR4 Expression in Early Breast Cancer and Risk of Distant Recurrence. <i>Oncologist</i> , 2009, 14, 1182-1188.	3.7	59
303	Rapamycin Regulates Stearoyl CoA Desaturase 1 Expression in Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 2770-2784.	4.1	59
304	Controlled Extracellular Matrix Degradation in Breast Cancer Tumors Improves Therapy by Trastuzumab. <i>Molecular Therapy</i> , 2011, 19, 479-489.	8.2	59
305	Expression of Long Noncoding RNA <i>YIYA</i> Promotes Glycolysis in Breast Cancer. <i>Cancer Research</i> , 2018, 78, 4524-4532.	0.9	59
306	Bile Acid Exposure Up-regulates Tuberous Sclerosis Complex 1/Mammalian Target of Rapamycin Pathway in Barrett's-Associated Esophageal Adenocarcinoma. <i>Cancer Research</i> , 2008, 68, 2632-2640.	0.9	58

#	ARTICLE	IF	CITATIONS
307	Downregulation of MicroRNA miR-520h by E1A Contributes to Anticancer Activity. <i>Cancer Research</i> , 2010, 70, 5096-5108.	0.9	58
308	Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer. <i>Cancer Cell</i> , 2018, 33, 752-769.e8.	16.8	58
309	Metastasis regulation by PPAR δ expression in cancer cells. <i>JCI Insight</i> , 2017, 2, e91419.	5.0	58
310	Targeting PKC δ as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer. <i>Cancer Cell</i> , 2018, 34, 954-969.e4.	16.8	56
311	HIF-1 α promotes autophagic proteolysis of Dicer and enhances tumor metastasis. <i>Journal of Clinical Investigation</i> , 2017, 128, 625-643.	8.2	56
312	Multiple cis- and trans-acting elements involved in regulation of the neu gene.. <i>Molecular and Cellular Biology</i> , 1990, 10, 6306-6315.	2.3	55
313	Electrospinning of silica nanochannels for single molecule detection. <i>Applied Physics Letters</i> , 2006, 88, 033106.	3.3	55
314	Rapamycin regulates the phosphorylation of rictor. <i>Biochemical and Biophysical Research Communications</i> , 2007, 362, 330-333.	2.1	55
315	Myocyte Enhancer Factor-2 Interacting Transcriptional Repressor (MITR) Is a Switch That Promotes Osteogenesis and Inhibits Adipogenesis of Mesenchymal Stem Cells by Inactivating Peroxisome Proliferator-activated Receptor δ -2. <i>Journal of Biological Chemistry</i> , 2011, 286, 10671-10680.	3.4	55
316	ASPH-notch Axis guided Exosomal delivery of Prometastatic Secretome renders breast Cancer multi-organ metastasis. <i>Molecular Cancer</i> , 2019, 18, 156.	19.2	55
317	Mitosis-specific Negative Regulation of Epidermal Growth Factor Receptor, Triggered by a Decrease in Ligand Binding and Dimerization, Can Be Overcome by Overexpression of Receptor. <i>Journal of Biological Chemistry</i> , 1997, 272, 18656-18665.	3.4	54
318	ErbB2-Mediated Src and Signal Transducer and Activator of Transcription 3 Activation Leads to Transcriptional Up-Regulation of p21Cip1 and Chemoresistance in Breast Cancer Cells. <i>Molecular Cancer Research</i> , 2009, 7, 592-600.	3.4	54
319	Epidermal Growth Factor Receptor Potentiates MCM7-Mediated DNA Replication through Tyrosine Phosphorylation of Lyn Kinase in Human Cancers. <i>Cancer Cell</i> , 2013, 23, 796-810.	16.8	54
320	Tyrosine 370 phosphorylation of ATM positively regulates DNA damage response. <i>Cell Research</i> , 2015, 25, 225-236.	12.0	54
321	Signaling Intricacies Take Center Stage in Cancer Cells: Figure 1.. <i>Cancer Research</i> , 2005, 65, 2511-2515.	0.9	53
322	PTEN self-regulates through USP11 via the PI3K-FOXO pathway to stabilize tumor suppression. <i>Nature Communications</i> , 2019, 10, 636.	12.8	53
323	A New Role of Protein Phosphatase 2A in Adenoviral E1A Protein-Mediated Sensitization to Anticancer Drug-Induced Apoptosis in Human Breast Cancer Cells. <i>Cancer Research</i> , 2004, 64, 5938-5942.	0.9	52
324	Targeting the EGFR/PCNA Signaling Suppresses Tumor Growth of Triple-Negative Breast Cancer Cells with Cell-Penetrating PCNA Peptides. <i>PLoS ONE</i> , 2013, 8, e61362.	2.5	52

#	ARTICLE	IF	CITATIONS
325	EGFR and c-MET Cooperate to Enhance Resistance to PARP Inhibitors in Hepatocellular Carcinoma. <i>Cancer Research</i> , 2019, 79, 819-829.	0.9	52
326	ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer. <i>Science Immunology</i> , 2022, 7, .	11.9	52
327	p27 Kip1 inhibits HER2/neu-mediated cell growth and tumorigenesis. <i>Oncogene</i> , 2001, 20, 3695-3702.	5.9	51
328	DOC-2/hDab-2 inhibits ILK activity and induces anoikis in breast cancer cells through an Akt-independent pathway. <i>Oncogene</i> , 2001, 20, 6960-6964.	5.9	51
329	Syntaxin 6-mediated Golgi translocation plays an important role in nuclear functions of EGFR through microtubule-dependent trafficking. <i>Oncogene</i> , 2014, 33, 756-770.	5.9	51
330	Oncogenic Functions of Gli1 in Pancreatic Adenocarcinoma Are Supported by Its PRMT1-Mediated Methylation. <i>Cancer Research</i> , 2016, 76, 7049-7058.	0.9	51
331	Nanoparticle Delivery of miR-34a Eradicates Long-term-cultured Breast Cancer Stem Cells via Targeting C22ORF28 Directly. <i>Theranostics</i> , 2017, 7, 4805-4824.	10.0	51
332	The lncRNA H19 alleviates muscular dystrophy by stabilizing dystrophin. <i>Nature Cell Biology</i> , 2020, 22, 1332-1345.	10.3	51
333	Altered Expression and Splicing of <i>ESRP1</i> in Malignant Melanoma Correlates with Epithelial-Mesenchymal Status and Tumor-Associated Immune Cytolytic Activity. <i>Cancer Immunology Research</i> , 2016, 4, 552-561.	3.4	50
334	HER2 overexpression and cancer targeting. <i>Seminars in Oncology</i> , 2001, 28, 115-124.	2.2	49
335	Antitumor agents. 258. Syntheses and evaluation of dietary antioxidant-taxoid conjugates as novel cytotoxic agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 5204-5209.	2.2	49
336	Tid1, CHIP and ErbB2 interactions and their prognostic implications for breast cancer patients. <i>Journal of Pathology</i> , 2011, 225, 424-437.	4.5	49
337	Regulation of Ubiquitination-Mediated Protein Degradation by Survival Kinases in Cancer. <i>Frontiers in Oncology</i> , 2012, 2, 15.	2.8	49
338	Automated electrorotation to reveal dielectric variations related to HER-2/neu overexpression in MCF-7 sublines. <i>Clinical Cancer Research</i> , 2002, 8, 615-9.	7.0	49
339	β -catenin nuclear localization is associated with grade in ovarian serous carcinoma. <i>Gynecologic Oncology</i> , 2003, 88, 363-368.	1.4	48
340	The ZNF304-integrin axis protects against anoikis in cancer. <i>Nature Communications</i> , 2015, 6, 7351.	12.8	48
341	Safety study and characterization of E1A-liposome complex gene-delivery protocol in an ovarian cancer model. <i>Gene Therapy</i> , 1998, 5, 1538-1544.	4.5	47
342	Brk/PTK6 sustains activated EGFR signaling through inhibiting EGFR degradation and transactivating EGFR. <i>Oncogene</i> , 2012, 31, 4372-4383.	5.9	47

#	ARTICLE	IF	CITATIONS
343	Aurora A kinase activates YAP signaling in triple-negative breast cancer. <i>Oncogene</i> , 2017, 36, 1265-1275.	5.9	47
344	Activation of Aurora A kinase increases YAP stability via blockage of autophagy. <i>Cell Death and Disease</i> , 2019, 10, 432.	6.3	47
345	A Phase I Multicenter Study of E1A Gene Therapy for Patients with Metastatic Breast Cancer and Epithelial Ovarian Cancer That Overexpresses HER-2/neu or Epithelial Ovarian Cancer. M.D. Anderson Cancer Center, Houston, Texas. <i>Human Gene Therapy</i> , 1998, 9, 1775-1798.	2.7	46
346	Signaling-Mediated Regulation of MicroRNA Processing. <i>Cancer Research</i> , 2015, 75, 783-791.	0.9	46
347	Amplification of the proto-neu oncogene facilitates oncogenic activation by a single point mutation.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1989, 86, 2545-2548.	7.1	45
348	Correlation of p27 protein expression with HER-2/neu expression in breast cancer. <i>Molecular Carcinogenesis</i> , 2001, 30, 169-175.	2.7	45
349	Assessing metastatic potential of breast cancer cells based on EGFR dynamics. <i>Scientific Reports</i> , 2019, 9, 3395.	3.3	45
350	Systemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A gene. <i>Cancer Research</i> , 2002, 62, 6712-6.	0.9	45
351	Colon cancer stem cells resist antiangiogenesis therapy-induced apoptosis. <i>Cancer Letters</i> , 2013, 328, 226-234.	7.2	44
352	PRMT1 enhances oncogenic arginine methylation of NONO in colorectal cancer. <i>Oncogene</i> , 2021, 40, 1375-1389.	5.9	44
353	Enhancement of Bik antitumor effect by Bik mutants. <i>Cancer Research</i> , 2003, 63, 7630-3.	0.9	44
354	Involvement of Co-activator p300 in the Transcriptional Regulation of the HER-2/neu Gene. <i>Journal of Biological Chemistry</i> , 1997, 272, 6101-6104.	3.4	43
355	Further Evidence for Expression and Function of the VEGF-C/VEGFR-3 Axis in Cancer Cells. <i>Cancer Cell</i> , 2008, 13, 557-560.	16.8	43
356	Nuclear EGFR Suppresses Ribonuclease Activity of Polynucleotide Phosphorylase through DNAPK-mediated Phosphorylation at Serine 776. <i>Journal of Biological Chemistry</i> , 2012, 287, 31015-31026.	3.4	43
357	Enhancer of Zeste Homolog 2 and Histone Deacetylase 9c Regulate Age-Dependent Mesenchymal Stem Cell Differentiation into Osteoblasts and Adipocytes. <i>Stem Cells</i> , 2016, 34, 2183-2193.	3.2	43
358	LncRNAs-directed PTEN enzymatic switch governs epithelialâ€“mesenchymal transition. <i>Cell Research</i> , 2019, 29, 286-304.	12.0	43
359	Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance. <i>Nature Communications</i> , 2021, 12, 7041.	12.8	43
360	Dominant-negative Mutants of Grb2 Induced Reversal of the Transformed Phenotypes Caused by the Point Mutation-activated Rat HER-2/Neu. <i>Journal of Biological Chemistry</i> , 1995, 270, 30717-30724.	3.4	42

#	ARTICLE	IF	CITATIONS
361	Enhanced paclitaxel cytotoxicity and prolonged animal survival rate by a nonviral-mediated systemic delivery of E1A gene in orthotopic xenograft human breast cancer. <i>Cancer Gene Therapy</i> , 2004, 11, 594-602.	4.6	42
362	FOXO3a-Dependent Mechanism of E1A-Induced Chemosensitization. <i>Cancer Research</i> , 2011, 71, 6878-6887.	0.9	42
363	ZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer. <i>Cell Reports</i> , 2018, 23, 823-837.	6.4	42
364	A noncoding RNA modulator potentiates phenylalanine metabolism in mice. <i>Science</i> , 2021, 373, 662-673.	12.6	42
365	Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing. <i>American Journal of Cancer Research</i> , 2018, 8, 1307-1316.	1.4	42
366	Safety studies of the intraperitoneal injection of E1A-liposome complex in mice. <i>Gene Therapy</i> , 1997, 4, 238-243.	4.5	41
367	Upregulation of IKK α /IKK β by integrin-linked kinase is required for HER2/neu-induced NF- κ B antiapoptotic pathway. <i>Oncogene</i> , 2004, 23, 3883-3887.	5.9	41
368	SRC-3 coactivator regulates cell resistance to cytotoxic stress via TRAF4-mediated p53 destabilization. <i>Genes and Development</i> , 2013, 27, 274-287.	5.9	41
369	Transcript maps of Drosophila yolk protein genes. <i>Journal of Molecular Biology</i> , 1982, 154, 581-602.	4.2	40
370	Different restriction enzyme-generated sticky DNA ends can be joined in vitro. <i>Nucleic Acids Research</i> , 1984, 12, 1863-1874.	14.5	40
371	Reduced growth rate and transformation phenotype of the prostate cancer cells by an interferon-inducible protein, p202. <i>Oncogene</i> , 1999, 18, 807-811.	5.9	40
372	Role for the double-stranded RNA activated protein kinase PKR in E2F-1-induced apoptosis. <i>Oncogene</i> , 2002, 21, 6278-6288.	5.9	40
373	The role of PRMT1 in EGFR methylation and signaling in MDA-MB-468 triple-negative breast cancer cells. <i>Breast Cancer</i> , 2018, 25, 74-80.	2.9	40
374	Cross-reactivity of C219 Anti-p170mdr-1 Antibody With p185c-erbB2 in Breast Cancer Cells: Cautions on Evaluating p170mdr-1. <i>Journal of the National Cancer Institute</i> , 1997, 89, 1524-1529.	6.3	39
375	HER2/neu in the management of invasive breast cancer. <i>Journal of the American College of Surgeons</i> , 2002, 194, 488-501.	0.5	39
376	Mechanisms of synthetic serine protease inhibitor (FUT-175)-mediated cell death. <i>Cancer</i> , 2007, 109, 2142-2153.	4.1	39
377	Acetylation of EGF receptor contributes to tumor cell resistance to histone deacetylase inhibitors. <i>Biochemical and Biophysical Research Communications</i> , 2011, 404, 68-73.	2.1	39
378	Suspension survival mediated by PP2A-STAT3-Col XVII determines tumour initiation and metastasis in cancer stem cells. <i>Nature Communications</i> , 2016, 7, 11798.	12.8	39

#	ARTICLE	IF	CITATIONS
379	HER2 overexpression and cancer targeting. <i>Seminars in Oncology</i> , 2001, 28, 115-124.	2.2	39
380	EZH2: a pivotal regulator in controlling cell differentiation. <i>American Journal of Translational Research (discontinued)</i> , 2012, 4, 364-75.	0.0	39
381	Length of the Linking Domain of Human pro-Tumor Necrosis Factor Determines the Cleavage Processing. <i>Biochemistry</i> , 1996, 35, 8226-8233.	2.5	38
382	Grb2 downregulation leads to Akt inactivation in heregulin-stimulated and ErbB2-overexpressing breast cancer cells. <i>Oncogene</i> , 2000, 19, 6271-6276.	5.9	38
383	Linear ubiquitination of cFLIP induced by LUBAC contributes to TNF α -induced apoptosis. <i>Journal of Biological Chemistry</i> , 2018, 293, 20062-20072.	3.4	38
384	Inhibition of cancer cell growth by BRCA2. <i>Cancer Research</i> , 2002, 62, 1311-4.	0.9	38
385	Interaction of Proliferation Cell Nuclear Antigen (PCNA) with c-Abl in Cell Proliferation and Response to DNA Damages in Breast Cancer. <i>PLoS ONE</i> , 2012, 7, e29416.	2.5	37
386	The suppression of colon cancer cell growth in nude mice by targeting β -catenin/TCF pathway. <i>Oncogene</i> , 2002, 21, 8340-8346.	5.9	36
387	ErbB-2 Induces the Cyclin D1 Gene in Prostate Epithelial Cells In vitro and In vivo. <i>Cancer Research</i> , 2007, 67, 4364-4372.	0.9	36
388	Different Redox States in Malignant and Nonmalignant Esophageal Epithelial Cells and Differential Cytotoxic Responses to Bile Acid and Honokiol. <i>Antioxidants and Redox Signaling</i> , 2009, 11, 1083-1095.	5.4	36
389	EGFR-SGLT1 interaction does not respond to EGFR modulators, but inhibition of SGLT1 sensitizes prostate cancer cells to EGFR tyrosine kinase inhibitors. <i>Prostate</i> , 2013, 73, 1453-1461.	2.3	36
390	Novel therapeutic strategy targeting the Hedgehog signalling and mTOR pathways in biliary tract cancer. <i>British Journal of Cancer</i> , 2015, 112, 1042-1051.	6.4	36
391	Differential Amplification of the TGF- β Gene in Human Gliomas. <i>European Journal of Implant and Refractive Surgery</i> , 1990, 2, 201-205.	0.3	36
392	Adenovirus type 5 E1A sensitizes hepatocellular carcinoma cells to gemcitabine. <i>Cancer Research</i> , 2003, 63, 6229-36.	0.9	36
393	Cytoplasmic/Nuclear Shuttling and Tumor Progression. <i>Annals of the New York Academy of Sciences</i> , 2005, 1059, 11-15.	3.8	35
394	Cancer targeted gene therapy of BikDD inhibits orthotopic lung cancer growth and improves long-term survival. <i>Oncogene</i> , 2009, 28, 3286-3295.	5.9	35
395	Mutant LKB1 Confers Enhanced Radiosensitization in Combination with Trametinib in KRAS-Mutant Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 5744-5756.	7.0	35
396	GSK3 β inactivation promotes the oncogenic functions of EZH2 and enhances methylation of H3K27 in human breast cancers. <i>Oncotarget</i> , 2016, 7, 57131-57144.	1.8	35

#	ARTICLE	IF	CITATIONS
397	Adenoviral E1A Targets Mdm4 to Stabilize Tumor Suppressor p53. <i>Cancer Research</i> , 2004, 64, 9080-9085.	0.9	34
398	Role of I β B kinase in tumorigenesis. <i>Future Oncology</i> , 2005, 1, 67-78.	2.4	34
399	An attenuated <i>Salmonella</i> oral DNA vaccine prevents the growth of hepatocellular carcinoma and colon cancer that express β -fetoprotein. <i>Cancer Gene Therapy</i> , 2006, 13, 746-752.	4.6	34
400	Nuclear translocation of the pro-apoptotic Bcl-2 family member Bok induces apoptosis. <i>Molecular Carcinogenesis</i> , 2006, 45, 73-83.	2.7	34
401	A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2375-2382.	4.1	34
402	The Beneficial Role of Sunitinib in Tumor Immune Surveillance by Regulating Tumor PD-L1. <i>Advanced Science</i> , 2021, 8, 2001596.	11.2	34
403	Targeting HER2: Recent developments and future directions for breast cancer patients. <i>Seminars in Oncology</i> , 2001, 28, 21-29.	2.2	33
404	TIE2-mediated tyrosine phosphorylation of H4 regulates DNA damage response by recruiting ABL1. <i>Science Advances</i> , 2016, 2, e1501290.	10.3	33
405	Suppression of stromal-derived Dickkopf-3 (DKK3) inhibits tumor progression and prolongs survival in pancreatic ductal adenocarcinoma. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	33
406	Selective Activation of Ceruloplasmin Promoter in Ovarian Tumors. <i>Cancer Research</i> , 2004, 64, 1788-1793.	0.9	32
407	The fabrication and testing of electrospun silica nanofiber membranes for the detection of proteins. <i>Nanotechnology</i> , 2008, 19, 445714.	2.6	32
408	Argininosuccinate synthetase 1 (ASS1) is a common metabolic marker of chemosensitivity for targeted arginine- and glutamine-starvation therapy. <i>Cancer Letters</i> , 2017, 388, 54-63.	7.2	32
409	S6K1 promotes invasiveness of breast cancer cells in a model of metastasis of triple-negative breast cancer. <i>American Journal of Translational Research (discontinued)</i> , 2014, 6, 361-76.	0.0	32
410	Antitumor agents 270. Novel substituted 6-phenyl-4H-furo[3,2-c]pyran-4-one derivatives as potent and highly selective anti-breast cancer agents. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 803-808.	3.0	31
411	Targeting the IKK β /mTOR/VEGF Signaling Pathway as a Potential Therapeutic Strategy for Obesity-Related Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 2212-2221.	4.1	31
412	Lapatinib-Mediated Cyclooxygenase-2 Expression via Epidermal Growth Factor Receptor/HuR Interaction Enhances the Aggressiveness of Triple-Negative Breast Cancer Cells. <i>Molecular Pharmacology</i> , 2013, 83, 857-869.	2.3	31
413	Inhibition of Type I Insulin-Like Growth Factor Receptor Signaling Attenuates the Development of Breast Cancer Brain Metastasis. <i>PLoS ONE</i> , 2013, 8, e73406.	2.5	31
414	miR326 Maturation Is Crucial for VEGF-Driven Cortactin Expression and Esophageal Cancer Progression. <i>Cancer Research</i> , 2014, 74, 6280-6290.	0.9	31

#	ARTICLE	IF	CITATIONS
415	HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer. <i>Molecular Oncology</i> , 2015, 9, 586-600.	4.6	31
416	Hepatoma cell-intrinsic TLR9 activation induces immune escape through PD-L1 upregulation in hepatocellular carcinoma. <i>Theranostics</i> , 2020, 10, 6530-6543.	10.0	31
417	Role of aromatic residues in the structure-function relationship of .alpha.-bungarotoxin. <i>Biochemistry</i> , 1982, 21, 2592-2600.	2.5	30
418	Changes inBRCA2Expression during Progression of the Cell Cycle. <i>Biochemical and Biophysical Research Communications</i> , 1997, 234, 247-251.	2.1	30
419	Association between ductal fluid proteomic expression profiles and the presence of lymph node metastases in women with breast cancer. <i>Surgery</i> , 2004, 136, 1061-1069.	1.9	30
420	Activation of p21(CIP1/WAF1) in mammary epithelium accelerates mammary tumorigenesis and promotes lung metastasis. <i>Biochemical and Biophysical Research Communications</i> , 2010, 403, 103-107.	2.1	30
421	Cancer Cell Metabolism Bolsters Immunotherapy Resistance by Promoting an Immunosuppressive Tumor Microenvironment. <i>Frontiers in Oncology</i> , 2020, 10, 1197.	2.8	30
422	Isolation of cancer-derived extracellular vesicle subpopulations by a size-selective microfluidic platform. <i>Biomicrofluidics</i> , 2020, 14, 034113.	2.4	29
423	miRNA-7/21/107 contribute to HBx-induced hepatocellular carcinoma progression through suppression of maspin. <i>Oncotarget</i> , 2015, 6, 25962-25974.	1.8	29
424	Adenovirus 5 E1A enhances histone deacetylase inhibitors-induced apoptosis through Egr-1-mediated Bim upregulation. <i>Oncogene</i> , 2010, 29, 5619-5629.	5.9	28
425	Segmentation of 3D Trajectories Acquired by TSUNAMI Microscope: An Application to EGFR Trafficking. <i>Biophysical Journal</i> , 2016, 111, 2214-2227.	0.5	28
426	In Vivo Targeting of ADAM9 Gene Expression Using Lentivirus-Delivered shRNA Suppresses Prostate Cancer Growth by Regulating REG4 Dependent Cell Cycle Progression. <i>PLoS ONE</i> , 2013, 8, e53795.	2.5	28
427	Phosphorylation of EZH2 at T416 by CDK2 contributes to the malignancy of triple negative breast cancers. <i>American Journal of Translational Research (discontinued)</i> , 2015, 7, 1009-20.	0.0	28
428	Negative autoregulation of the neu gene is mediated by a novel enhancer.. <i>Molecular and Cellular Biology</i> , 1992, 12, 2739-2748.	2.3	27
429	Human Pro-Tumor Necrosis Factor: Molecular Determinants of Membrane Translocation, Sorting, and Maturation. <i>Molecular and Cellular Biology</i> , 1995, 15, 6398-6405.	2.3	27
430	The erbB2 gene as a cancer therapeutic target and the tumor- and metastasis-suppressing function of E1A. , 1998, 17, 195-202.		27
431	Preclinical and clinical study of HER-2/neu-targeting cancer gene therapy. <i>Advanced Drug Delivery Reviews</i> , 1998, 30, 219-227.	13.7	27
432	Bcl-2 Antisense Oligonucleotide Overcomes Resistance to E1A Gene Therapy in a Low HER2-Expressing Ovarian Cancer Xenograft Model. <i>Cancer Research</i> , 2005, 65, 8406-8413.	0.9	27

#	ARTICLE	IF	CITATIONS
433	Upregulation of lactate dehydrogenase a by 14-3-3 η leads to increased glycolysis critical for breast cancer initiation and progression. <i>Oncotarget</i> , 2016, 7, 35270-35283.	1.8	27
434	A Positive TGF- β 2/c-KIT Feedback Loop Drives Tumor Progression in Advanced Primary Liver Cancer. <i>Neoplasia</i> , 2016, 18, 371-386.	5.3	27
435	De-acetylation and degradation of HSPA5 is critical for E1A metastasis suppression in breast cancer cells. <i>Oncotarget</i> , 2014, 5, 10558-10570.	1.8	27
436	Identification and characterization of a novel enhancer for the rat neu promoter.. <i>Molecular and Cellular Biology</i> , 1991, 11, 1875-1882.	2.3	26
437	p66Shc isoform Down-Regulated and Not Required for HER-2/neu Signaling Pathway in Human Breast Cancer Cell Lines with HER-2/neu Overexpression. <i>Biochemical and Biophysical Research Communications</i> , 1996, 221, 140-145.	2.1	26
438	Mapping of adenovirus 5 E1A domains responsible for suppression of neu-mediated transformation via transcriptional repression of neu. <i>Oncogene</i> , 1997, 14, 1965-1971.	5.9	26
439	The Role of p27 Kip1 in Dasatinib-Enhanced Paclitaxel Cytotoxicity in Human Ovarian Cancer Cells. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1403-1422.	6.3	26
440	Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancer. <i>Oncogene</i> , 2016, 35, 2186-2196.	5.9	26
441	Developmental Control of Drosophila Yolk Protein 1 Gene by cis-acting DNA Elements. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 1985, 50, 521-526.	1.1	26
442	Deglycosylation of PD-L1 by 2-deoxyglucose reverses PARP inhibitor-induced immunosuppression in triple-negative breast cancer. <i>American Journal of Cancer Research</i> , 2018, 8, 1837-1846.	1.4	26
443	Novel targets of Akt, p21, and MDM2. <i>Seminars in Oncology</i> , 2002, 29, 62-70.	2.2	25
444	Suppression of pancreatic tumor progression by systemic delivery of a pancreatic-cancer-specific promoter driven Bik mutant. <i>Cancer Letters</i> , 2006, 236, 58-63.	7.2	25
445	Inefficient proteasomal-degradation pathway stabilizes AP-2 β and activates HER-2/neu gene in breast cancer. <i>International Journal of Cancer</i> , 2006, 118, 802-811.	5.1	25
446	Direct sequencing analysis of transmembrane region of human neu gene by polymerase chain reaction. <i>Molecular Carcinogenesis</i> , 2006, 3, 198-201.	2.7	25
447	Clinical Biology of Esophageal Adenocarcinoma after Surgery Is Influenced by Nuclear Factor- κ B Expression. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 1200-1205.	2.5	25
448	TNF α induces HIF-1 α expression through activation of IKK β . <i>Biochemical and Biophysical Research Communications</i> , 2009, 389, 640-644.	2.1	25
449	Targeted hepatocellular carcinoma proapoptotic BikDD gene therapy. <i>Oncogene</i> , 2011, 30, 1773-1783.	5.9	25
450	Hepatitis B virus X protein induces IKK α nuclear translocation via Akt-dependent phosphorylation to promote the motility of hepatocarcinoma cells. <i>Journal of Cellular Physiology</i> , 2012, 227, 1446-1454.	4.1	25

#	ARTICLE	IF	CITATIONS
451	Severe Hepatitis Promotes Hepatocellular Carcinoma Recurrence via NF- κ B Pathway-Mediated Epithelial \rightarrow Mesenchymal Transition after Resection. <i>Clinical Cancer Research</i> , 2016, 22, 1800-1812.	7.0	25
452	Non-canonical signaling mode of the epidermal growth factor receptor family. <i>American Journal of Cancer Research</i> , 2015, 5, 2944-58.	1.4	25
453	Cell cycle-dependent regulation of p185neu: a relationship between disruption of this regulation and transformation.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995, 92, 1092-1096.	7.1	24
454	Transcription-coupled DNA Repair Is Genomic Context-dependent. <i>Journal of Biological Chemistry</i> , 2002, 277, 12777-12783.	3.4	24
455	Molecular Mechanisms in Barrett's Metaplasia and Its Progression. <i>Seminars in Oncology</i> , 2007, 34, S2-S6.	2.2	24
456	Aberrant Expression of proTPRN2 in Cancer Cells Confers Resistance to Apoptosis. <i>Cancer Research</i> , 2015, 75, 1846-1858.	0.9	24
457	Lymphotoxin- β 2 Interacts with Methylated EGFR to Mediate Acquired Resistance to Cetuximab in Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4388-4401.	7.0	24
458	Characterization of rodent epidermal growth factor receptor transcripts using a mouse genomic probe. <i>Biochemical and Biophysical Research Communications</i> , 1986, 141, 1109-1115.	2.1	23
459	Targeted Expression of BikDD Eliminates Breast Cancer with Virtually No Toxicity in Noninvasive Imaging Models. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1915-1924.	4.1	23
460	EZH2 expression correlates with locoregional recurrence after radiation in inflammatory breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014, 33, 58.	8.6	23
461	RGS2-mediated translational control mediates cancer cell dormancy and tumor relapse. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	23
462	EPOX Inhibits Angiogenesis by Degradation of Mcl-1 through ERK Inactivation. <i>Clinical Cancer Research</i> , 2009, 15, 4904-4914.	7.0	22
463	Expanding the arsenal: Metformin for the treatment of triple-negative breast cancer?. <i>Cell Cycle</i> , 2009, 8, 2681-2684.	2.6	22
464	Inhibition of VEGF165/VEGFR2-dependent signaling by LECT2 suppresses hepatocellular carcinoma angiogenesis. <i>Scientific Reports</i> , 2016, 6, 31398.	3.3	22
465	Juxtacrine Signaling Inhibits Antitumor Immunity by Upregulating PD-L1 Expression. <i>Cancer Research</i> , 2018, 78, 3761-3768.	0.9	22
466	Chemo-signal therapy, an emerging new approach to modify drug resistance in breast cancer. <i>Cancer Treatment Reviews</i> , 1999, 25, 271-277.	7.7	21
467	Antitumor activity of an Ets protein, PEA3, in breast cancer cell lines MDA-MB-361DYT2 and BT474M1. <i>Molecular Carcinogenesis</i> , 2006, 45, 667-675.	2.7	21
468	CONFORMATIONAL STABILITY OF A SNAKE CARDIOTOXIN. <i>International Journal of Peptide and Protein Research</i> , 1977, 10, 277-285.	0.1	21

#	ARTICLE	IF	CITATIONS
469	Oxygen sensor boosts growth factor signaling. <i>Nature Medicine</i> , 2009, 15, 246-247.	30.7	21
470	Antitumor Agents. 282. 2- <i>O</i> -Acetylglauucarubinone, a Quassinoid from <i>Odyendyca gabonensis</i> As a Potential Anti-Breast and Anti-Ovarian Cancer Agent. <i>Journal of Natural Products</i> , 2010, 73, 1553-1558.	3.0	21
471	Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin- <i>Cytosine Deaminase</i> - <i>Uracil Phosphoribosyltransferase</i> . <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1327-1336.	4.1	21
472	Novel Approaches for Chemosensitization of Breast Cancer Cells: The E1A Story. <i>Advances in Experimental Medicine and Biology</i> , 2007, 608, 144-169.	1.6	21
473	Beyond anti-VEGF: dual-targeting antiangiogenic and antiproliferative therapy. <i>American Journal of Translational Research (discontinued)</i> , 2013, 5, 393-403.	0.0	21
474	Extracellular PKM2 induces cancer proliferation by activating the EGFR signaling pathway. <i>American Journal of Cancer Research</i> , 2016, 6, 628-38.	1.4	21
475	E1A: Tumor suppressor or oncogene? Preclinical and clinical investigations of E1A gene therapy. <i>Breast Cancer</i> , 2001, 8, 285-293.	2.9	20
476	Transcriptional upregulation and activation of p53Cdc via p34cdc2 in Taxol-induced apoptosis. <i>Oncogene</i> , 2001, 20, 2537-2543.	5.9	20
477	The effects of Photofrin-mediated photodynamic therapy on the modulation of EGFR in esophageal squamous cell carcinoma cells. <i>Lasers in Medical Science</i> , 2013, 28, 605-614.	2.1	20
478	Targeted endostatin-cytosine deaminase fusion gene therapy plus 5-fluorocytosine suppresses ovarian tumor growth. <i>Oncogene</i> , 2013, 32, 1082-1090.	5.9	20
479	E1A-Mediated Inhibition of HSPA5 Suppresses Cell Migration and Invasion in Triple-Negative Breast Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 889-898.	1.5	20
480	Induction of NKG2D Ligands on Solid Tumors Requires Tumor-Specific CD8+ T Cells and Histone Acetyltransferases. <i>Cancer Immunology Research</i> , 2017, 5, 300-311.	3.4	20
481	Functional roles of the human ribonuclease A superfamily in RNA metabolism and membrane receptor biology. <i>Molecular Aspects of Medicine</i> , 2019, 70, 106-116.	6.4	20
482	H2O2 induces nuclear transport of the receptor tyrosine kinase c-MET in breast cancer cells via a membrane-bound retrograde trafficking mechanism. <i>Journal of Biological Chemistry</i> , 2019, 294, 8516-8528.	3.4	20
483	Targeting positive feedback between BASP1 and EGFR as a therapeutic strategy for lung cancer progression. <i>Theranostics</i> , 2020, 10, 10925-10939.	10.0	20
484	Cigarette smoke-induced LKB1/AMPK pathway deficiency reduces EGFR TKI sensitivity in NSCLC. <i>Oncogene</i> , 2021, 40, 1162-1175.	5.9	20
485	Scutellaria barbata D. Don Inhibits the Main Proteases (Mpro and TMPRSS2) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. <i>Viruses</i> , 2021, 13, 826.	3.3	20
486	Sciellin mediates mesenchymal-to-epithelial transition in colorectal cancer hepatic metastasis. <i>Oncotarget</i> , 2016, 7, 25742-25754.	1.8	20

#	ARTICLE	IF	CITATIONS
487	PARG inhibition limits HCC progression and potentiates the efficacy of immune checkpoint therapy. <i>Journal of Hepatology</i> , 2022, 77, 140-151.	3.7	20
488	Effectiveness of water soluble poly(L-glutamic acid)-camptothecin conjugate against resistant human lung cancer xenografted in nude mice. <i>International Journal of Oncology</i> , 2001, 18, 331-6.	3.3	19
489	The suppression of MAD1 by AKT-mediated phosphorylation activates MAD1 target genes transcription. <i>Molecular Carcinogenesis</i> , 2009, 48, 1048-1058.	2.7	19
490	The role of T-cell immunoglobulin mucin-3 and its ligand galectin-9 in antitumor immunity and cancer immunotherapy. <i>Science China Life Sciences</i> , 2017, 60, 1058-1064.	4.9	19
491	E1A Sensitizes Cancer Cells to TRAIL-Induced Apoptosis through Enhancement of Caspase Activation. <i>Molecular Cancer Research</i> , 2005, 3, 219-226.	3.4	19
492	MZF-1/Elk-1 interaction domain as therapeutic target for protein kinase C δ -based triple-negative breast cancer cells. <i>Oncotarget</i> , 2016, 7, 59845-59859.	1.8	18
493	The NH(2)-terminal and conserved region 2 domains of adenovirus E1A mediate two distinct mechanisms of tumor suppression. <i>Cancer Research</i> , 2002, 62, 346-50.	0.9	18
494	The adenoviral E1A induces p21WAF1/CIP1 expression in cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2003, 305, 1099-1104.	2.1	17
495	Expression of PEA3 and Lack of Correlation Between PEA3 and HER-2/neu Expression in Breast Cancer. <i>Breast Cancer Research and Treatment</i> , 2006, 98, 295-301.	2.5	17
496	Endostatin-Cytosine Deaminase Fusion Protein Suppresses Tumor Growth by Targeting Neovascular Endothelial Cells. <i>Cancer Research</i> , 2006, 66, 378-384.	0.9	17
497	Activation of Murine Double Minute 2 by Akt in Mammary Epithelium Delays Mammary Involution and Accelerates Mammary Tumorigenesis. <i>Cancer Research</i> , 2010, 70, 7684-7689.	0.9	17
498	Expression of metastasis suppressor BRMS1 in breast cancer cells results in a marked delay in cellular adhesion to matrix. <i>Molecular Carcinogenesis</i> , 2014, 53, 1011-1026.	2.7	17
499	Dicer Elicits Paclitaxel Chemosensitization and Suppresses Cancer Stemness in Breast Cancer by Repressing AXL. <i>Cancer Research</i> , 2016, 76, 3916-3928.	0.9	17
500	New Approaches on Cancer Immunotherapy. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 10, a036863.	6.2	17
501	Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. <i>Pancreatology</i> , 2020, 20, 101-109.	1.1	17
502	Arrest-defective-1 protein (ARD1): tumor suppressor or oncoprotein?. <i>American Journal of Translational Research (discontinued)</i> , 2010, 2, 56-64.	0.0	17
503	MRNIP condensates promote DNA double-strand break sensing and end resection. <i>Nature Communications</i> , 2022, 13, 2638.	12.8	17
504	In Vitro Synthesis of an N-myristoylated Fusion Protein That Binds to the Liposomal Surface. <i>Archives of Biochemistry and Biophysics</i> , 1996, 326, 179-184.	3.0	16

#	ARTICLE	IF	CITATIONS
505	Characterization of BRCA2: temperature sensitivity of detection and cell-cycle regulated expression. <i>Oncogene</i> , 1998, 17, 2377-2381.	5.9	16
506	Interferon- α -inducible protein IFI λ inhibits cell invasion by upregulating the metastasis suppressor maspin. <i>Molecular Carcinogenesis</i> , 2008, 47, 739-743.	2.7	16
507	Phosphorylation of ARD1 by IKK β contributes to its destabilization and degradation. <i>Biochemical and Biophysical Research Communications</i> , 2009, 389, 156-161.	2.1	16
508	Implication of nuclear EGFR in the development of resistance to anticancer therapies. <i>BioMedicine</i>		

#	ARTICLE	IF	CITATIONS
523	The Anti-Tumor Activity of E1A and its Implications in Cancer Therapy. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2014, 62, 195-204.	2.3	14
524	Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2021, 74, 907-918.	3.7	14
525	Abstract 5169: Flow-proteomic analysis of single signaling complex.. , 2013, , .		14
526	The status of tyrosyl residues in a Formosan cobra cardiotoxin. <i>Biochimica Et Biophysica Acta (BBA) - Protein Structure</i> , 1978, 535, 178-187.	1.7	13
527	Prostate-specific antitumor activity by probasin promoter-directed p202 expression. <i>Molecular Carcinogenesis</i> , 2003, 37, 130-137.	2.7	13
528	Targeted BikDD Expression Kills Androgen-Dependent and Castration-Resistant Prostate Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 1813-1825.	4.1	13
529	BIK ubiquitination by the E3 ligase Cul5-ASB11 determines cell fate during cellular stress. <i>Journal of Cell Biology</i> , 2019, 218, 3002-3018.	5.2	13
530	Musashi-1 promotes stress-induced tumor progression through recruitment of AGO2. <i>Theranostics</i> , 2020, 10, 201-217.	10.0	13
531	Hereditary retinoblastoma iPSC model reveals aberrant spliceosome function driving bone malignancies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2117857119.	7.1	13
532	Identification of a Specific DNA Region Required for Enhanced Transcription of HER2/neu in the MDA-MB453 Breast Cancer Cell Line. <i>DNA and Cell Biology</i> , 1996, 15, 749-757.	1.9	12
533	PARP inhibitors as precision medicine for cancer treatment. <i>National Science Review</i> , 2017, 4, 576-592.	9.5	12
534	Intracaeal Orthotopic Colorectal Cancer Xenograft Mouse Model. <i>Bio-protocol</i> , 2017, 7, .	0.4	12
535	Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells. <i>American Journal of Cancer Research</i> , 2019, 9, 608-618.	1.4	12
536	Tafenoquine and its derivatives as inhibitors for the severe acute respiratory syndrome coronavirus 2. <i>Journal of Biological Chemistry</i> , 2022, 298, 101658.	3.4	12
537	Ceramide does not act as a general second messenger for ultraviolet-induced apoptosis. <i>Oncogene</i> , 2002, 21, 44-52.	5.9	11
538	A delayed chemically induced tumorigenesis in Brca2 mutant mice. <i>Oncogene</i> , 2004, 23, 1896-1901.	5.9	11
539	High speed digital protein interaction analysis using microfluidic single molecule detection system. <i>Lab on A Chip</i> , 2010, 10, 1793.	6.0	11
540	Identification of a G1±G1²î³, AKT and PKCÎ± signalome associated with invasive growth in two genetic models of human breast cancer cell epithelial-to-mesenchymal transition. <i>International Journal of Oncology</i> , 2012, 41, 189-200.	3.3	11

#	ARTICLE	IF	CITATIONS
541	The effect of ephrin-A1 on resistance to Photofrin-mediated photodynamic therapy in esophageal squamous cell carcinoma cells. <i>Lasers in Medical Science</i> , 2015, 30, 2353-2361.	2.1	11
542	Human ribonuclease 1 serves as a secretory ligand of ephrin A4 receptor and induces breast tumor initiation. <i>Nature Communications</i> , 2021, 12, 2788.	12.8	11
543	Sodium/Glucose Co-transporter 1 Expression Increases in Human Diseased Prostate. <i>Journal of Cancer Science & Therapy</i> , 2012, 04, .	1.7	11
544	Triplex formation at the rat neu oncogene promoter. <i>Gene</i> , 1994, 149, 109-114.	2.2	10
545	HER-2/Neu signaling and therapeutic approaches in breast cancer. <i>Breast Disease</i> , 2002, 15, 13-24.	0.8	10
546	A novel CRM1-dependent nuclear export signal in adenoviral E1A protein regulated by phosphorylation. <i>FASEB Journal</i> , 2006, 20, 2603-2605.	0.5	10
547	Microfluidic three-dimensional hydrodynamic flow focusing for the rapid protein concentration analysis. <i>Biomicrofluidics</i> , 2012, 6, 24132.	2.4	10
548	POMC maintains tumor-initiating properties of tumor tissue-derived long-term-cultured breast cancer stem cells. <i>International Journal of Cancer</i> , 2017, 140, 2517-2525.	5.1	10
549	Expression and Clinical Significance of Protein Kinase RNA-Like Endoplasmic Reticulum Kinase and Phosphorylated Eukaryotic Initiation Factor 2 \pm in Pancreatic Ductal Adenocarcinoma. <i>Pancreas</i> , 2019, 48, 323-328.	1.1	10
550	Rational combination of immunotherapy for triple negative breast cancer treatment. <i>Chinese Clinical Oncology</i> , 2017, 6, 54-54.	1.2	10
551	The role of amino functions in recombinant human tumor necrosis factor in expression of biological activity. <i>Molecular Immunology</i> , 1992, 29, 77-81.	2.2	9
552	Greater Enhancement of Chemosensitivity by Caffeine in High-p185neu-Expressing Human Non-Small-Cell Lung Cancer Cell Lines. <i>Journal of the National Cancer Institute</i> , 1994, 86, 1018-1020.	6.3	9
553	Involvement of cdc2-mediated phosphorylation in the cell cycle-dependent regulation of p185neu. <i>Oncogene</i> , 1997, 15, 2633-2641.	5.9	9
554	Molecular profile of advanced-stage transitional cell carcinoma of the ovary. <i>American Journal of Obstetrics and Gynecology</i> , 1997, 177, 120-125.	1.3	9
555	Inhibition of focal contact formation in cells transformed by p185neu. <i>Molecular Carcinogenesis</i> , 1999, 25, 150-154.	2.7	9
556	Localizing the EGF receptor - Reply. <i>Nature Cell Biology</i> , 2002, 4, E22-E23.	10.3	9
557	Rapid detection of two-protein interaction with a single fluorophore by using a microfluidic device. <i>Analyst</i> , The, 2010, 135, 2907.	3.5	9
558	Establishment of a human embryonic stem cell line with homozygous TP53 R248W mutant by TALEN mediated gene editing. <i>Stem Cell Research</i> , 2018, 29, 215-219.	0.7	9

#	ARTICLE	IF	CITATIONS
559	A homozygous p53 R282W mutant human embryonic stem cell line generated using TALEN-mediated precise gene editing. <i>Stem Cell Research</i> , 2018, 27, 131-135.	0.7	9
560	A novel ligand-receptor relationship between families of ribonucleases and receptor tyrosine kinases. <i>Journal of Biomedical Science</i> , 2018, 25, 83.	7.0	9
561	A chirality-dependent action of vitamin C in suppressing Kirsten rat sarcoma mutant tumor growth by the oxidative combination: Rationale for cancer therapeutics. <i>International Journal of Cancer</i> , 2020, 146, 2822-2828.	5.1	9
562	PKC β -mediated SGLT1 upregulation confers the acquired resistance of NSCLC to EGFR TKIs. <i>Oncogene</i> , 2021, 40, 4796-4808.	5.9	9
563	Regulation of therapeutic resistance in cancers by receptor tyrosine kinases. <i>American Journal of Cancer Research</i> , 2016, 6, 827-42.	1.4	9
564	MECHANISMS OF DEREGLATED HER2/NEU EXPRESSION IN BREAST-CANCER CELL-LINES. <i>International Journal of Oncology</i> , 1994, 4, 599-608.	3.3	8
565	Finding the bEST routes to cancer. <i>Cancer Biology and Therapy</i> , 2004, 3, 1090-1091.	3.4	8

566

#	ARTICLE	IF	CITATIONS
577	Suppressing HER2/neu-Mediated Cell Transformation by Transcriptional Repressors. <i>Breast Disease</i> , 2000, 11, 133-144.	0.8	6
578	Adenovirus-mediated N5 gene transfer inhibits tumor cell proliferation by induction of apoptosis. <i>Cancer Gene Therapy</i> , 2000, 7, 985-990.	4.6	6
579	Pneumatically Actuated Soft Micromold Device for Fabricating Collagen and Matrigel Microparticles. <i>Soft Robotics</i> , 2017, 4, 390-399.	8.0	6
580	A flow-proteomic platform for analyzing protein concentration (FAP): Proof of concept for quantification of PD-L1 protein in cells and tissues. <i>Biosensors and Bioelectronics</i> , 2018, 117, 97-103.	10.1	6
581	Evading immune surveillance via tyrosine phosphorylation of nuclear PCNA. <i>Cell Reports</i> , 2021, 36, 109537.	6.4	6
582	Targeting HER-2/neu-Overexpressing Cancer Cells with Transcriptional Repressor Genes Delivered by Cationic Liposome. , 1999, , 357-377.		6
583	Measurement of Protein 53 Diffusion Coefficient in Live HeLa Cells Using Raster Image Correlation Spectroscopy (RICS). <i>Journal of Biomaterials and Nanobiotechnology</i> , 2010, 01, 31-36.	0.5	6
584	The potential role of YAP in Axl-mediated resistance to EGFR tyrosine kinase inhibitors. <i>American Journal of Cancer Research</i> , 2019, 9, 2719-2729.	1.4	6
585	High RPS3A expression correlates with low tumor immune cell infiltration and unfavorable prognosis in hepatocellular carcinoma patients. <i>American Journal of Cancer Research</i> , 2020, 10, 2768-2784.	1.4	6
586	Renaturation of a reduced Taiwan cobra cardiotoxin. <i>Biochimica Et Biophysica Acta (BBA) - Protein Structure</i> , 1978, 533, 105-111.	1.7	5
587	Receptor Tyrosine Kinases in the Nucleus: Nuclear Functions and Therapeutic Implications in Cancers. <i>Cancer Drug Discovery and Development</i> , 2014, , 189-229.	0.4	5
588	Targeted expression of BikDD combined with metronomic doxorubicin induces synergistic antitumor effect through Bax activation in hepatocellular carcinoma. <i>Oncotarget</i> , 2015, 6, 23807-23819.	1.8	5
589	Exogenous expression of human SGLT1 exhibits aggregations in sodium dodecyl sulfate polyacrylamide gel electrophoresis. <i>American Journal of Translational Research (discontinued)</i> , 2013, 5, 441-9.	0.0	5
590	Proteasome inhibition enhances the killing effect of BikDD gene therapy. <i>American Journal of Translational Research (discontinued)</i> , 2015, 7, 319-27.	0.0	5
591	Inhibition of c-MET upregulates PD-L1 expression in lung adenocarcinoma. <i>American Journal of Cancer Research</i> , 2020, 10, 564-571.	1.4	5
592	Differential activity of the RVF enhancer element in the decreased expression of the neu oncogene in NR-6 cells versus parental Swiss Webster 3T3 cells. <i>Molecular Carcinogenesis</i> , 1993, 7, 44-49.	2.7	4
593	Cytoplasmic expression of p21CIP1/WAF1 is correlated with IKK β overexpression in human breast cancers. <i>International Journal of Oncology</i> , 2006, 29, 1103.	3.3	4
594	Powering Tumor Metastasis with Recycled Fuel. <i>Cancer Cell</i> , 2016, 30, 374-375.	16.8	4

#	ARTICLE	IF	CITATIONS
595	Racial profiling harms science. <i>Science</i> , 2019, 363, 1290-1292.	12.6	4
596	E1A Cancer Gene Therapy. , 2002, , 465-477.		4
597	Abstract A49: S6K1 promotes invasiveness of breast cancer cells in a novel model of triple-negative breast cancer metastasis. , 2014, , .		4
598	An essential role of PRMT1-mediated EGFR methylation in EGFR activation by ribonuclease 5. <i>American Journal of Cancer Research</i> , 2019, 9, 180-185.	1.4	4
599	Inhibition of CDK2 reduces EZH2 phosphorylation and reactivates ER α expression in high-grade serous ovarian carcinoma. <i>American Journal of Cancer Research</i> , 2020, 10, 1194-1206.	1.4	4
600	Endothelial p130cas confers resistance to anti-angiogenesis therapy. <i>Cell Reports</i> , 2022, 38, 110301.	6.4	4
601	Prospects of the potential strategies to improve the efficacy of anti-PD-1/PD-L1 therapy. <i>Clinical and Translational Medicine</i> , 2022, 12, e803.	4.0	4
602	A novel alteration in the epidermal growth factor receptor gene is frequently detected in human non-small cell lung cancer. <i>Lung Cancer</i> , 1990, 6, 65-72.	2.0	3
603	E1A Is an Oncogene and May Immortalize Normal Cells, Especially in Combination With Other Oncoproteins. <i>Journal of Clinical Oncology</i> , 2001, 19, 4183-4184.	1.6	3
604	Delivery of DNA to Tumor Cells Using Cationic Liposomes. , 2004, 245, 125-136.		3
605	I κ B Kinase Promotes Tumorigenesis through Inhibition of Forkhead FOXO3a. <i>Cell</i> , 2007, 129, 1427-1428.	28.9	3
606	Regulation of Breast Cancer Metastasis by Atypical Chemokine Receptors. <i>Clinical Cancer Research</i> , 2009, 15, 2951-2953.	7.0	3
607	Expression of Autotaxin and Lysophosphatidic Acid Receptors Increases Mammary Tumorigenesis, Invasion, and Metastases. <i>Cancer Cell</i> , 2009, 16, 172.	16.8	3
608	On Mammary Gland Growth Factors: Roles in Normal Development and in Cancer. <i>Cold Spring Harbor Perspectives in Biology</i> , 2012, 4, a013532-a013532.	5.5	3
609	Development of automated high throughput single molecular microfluidic detection platform for signal transduction analysis. <i>Proceedings of SPIE</i> , 2016, , .	0.8	3
610	Analysis of Individual Signaling Complexes by mMAPS, a Flow- μ Proteomic System. <i>Current Protocols in Molecular Biology</i> , 2016, 114, 20.11.1-20.11.22.	2.9	3
611	Generation of an induced pluripotent stem cell line from an individual with a heterozygous RECQL4 mutation. <i>Stem Cell Research</i> , 2018, 33, 36-40.	0.7	3
612	PP2A Deficiency Enhances Carcinogenesis of Lgr5+ Intestinal Stem Cells Both in Organoids and In Vivo. <i>Cells</i> , 2020, 9, 90.	4.1	3

#	ARTICLE	IF	CITATIONS
613	The N-linked glycosylations of TIGIT Asn32 and Asn101 facilitate PVR/TIGIT interaction. <i>Biochemical and Biophysical Research Communications</i> , 2021, 562, 9-14.	2.1	3
614	Nuclear Functions and Trafficking of Receptor Tyrosine Kinases. , 2013, , 159-176.		3
615	Advances in Liposome-Based Targeted Gene Therapy of Cancer. , 2012, , 113-133.		3
616	A tumor vessel-targeting fusion protein elicits a chemotherapeutic bystander effect in pancreatic ductal adenocarcinoma. <i>American Journal of Cancer Research</i> , 2017, 7, 657-672.	1.4	3
617	Differential expression of the neu oncogene in mouse liver and pancreatic cell lines. <i>Biochemical and Biophysical Research Communications</i> , 1992, 186, 363-370.	2.1	2
618	RODENT P53 SUPPRESSES THE TRANSFORMING ACTIVITY OF THE ACTIVATED NEU ONCOGENE BY MODULATING THE BASAL PROMOTER ACTIVITY OF NEU. <i>International Journal of Oncology</i> , 1995, 6, 1087-92.	3.3	2
619	Discussion: Molecular Therapeutics and Pharmacogenomics. <i>Gynecologic Oncology</i> , 2003, 88, S93-S96.	1.4	2
620	Novel Signaling Pathways in Breast Cancer. , 2006, , 823-839.		2
621	Correction: Reduced P27kip1 and Trastuzumab Resistance. <i>Cancer Research</i> , 2008, 68, 10005-10005.	0.9	2
622	Nanofluidic Devices for Single Molecule Identification. <i>Journal of Photopolymer Science and Technology</i> = [Fotoporima Konwakai Shi], 2008, 21, 531-536.	0.3	2
623	Efficient systemic DNA delivery to the tumor by self-assembled nanoparticle. <i>Journal of Nanoparticle Research</i> , 2014, 16, 1.	1.9	2
624	Digital Receptor Occupancy Assay in Quantifying On- and Off-Target Binding Affinities of Therapeutic Antibodies. <i>ACS Sensors</i> , 2020, 5, 296-302.	7.8	2
625	A novel splice variant of HER2 with increased transformation activity. , 1998, 23, 62.		2
626	Biochemical Fractionation of Membrane Receptors in the Nucleus. <i>Methods in Molecular Biology</i> , 2015, 1234, 99-112.	0.9	2
627	Abstract 989: The crosstalk of mTOR/S6K1 and Hedgehog pathways. , 2012, , .		2
628	CDK4/6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: Are we at the finish line?. <i>Oncotarget</i> , 2018, 9, 34193-34195.	1.8	2
629	Arginine methylation of EGFR: a new biomarker for predicting resistance to anti-EGFR treatment. <i>American Journal of Cancer Research</i> , 2017, 7, 2587-2599.	1.4	2
630	Single oral dose acute and subacute toxicity of a c-MET tyrosine kinase inhibitor and CDK 4/6 inhibitor combination drug therapy. <i>American Journal of Cancer Research</i> , 2018, 8, 183-191.	1.4	2

#	ARTICLE	IF	CITATIONS
631	Nuclear translocation of the receptor tyrosine kinase c-MET reduces the treatment efficacies of olaparib and gemcitabine in pancreatic ductal adenocarcinoma cells. American Journal of Cancer Research, 2021, 11, 236-250.	1.4	2
632	An optimized protocol for PD-L1 pathological assessment with patient sample deglycosylation to improve correlation with therapeutic response. STAR Protocols, 2022, 3, 101198.	1.2	2
633	COMPLEX REGULATION OF THE ADENOVIRUS E2 PROMOTER BY THE VIRAL ONCOPROTEINS E1A AND E7 AND TUMOR-SUPPRESSOR RB. International Journal of Oncology, 1994, 4, 109-15.	3.3	1
634	HER2 NEU OVEREXPRESSION COUNTERACTS THE GROWTH EFFECTS OF C-MYC IN BREAST-CANCER CELLS. International Journal of Oncology, 1994, 4, 965-9.	3.3	1
635	Hyperthermia Enhances the Cytotoxicity of National Institutes of Health 3T3 Cells Transfected with a Noncleavable Transmembrane Pro-Tumor Necrosis Factor Deletion Mutant. Journal of Immunotherapy, 1994, 16, 181-187.	2.4	1
636	Nuclear Functions of Receptor Tyrosine Kinases. , 2015, , 77-109.		1
637	Breast Cancer Gene Therapy. , 2006, , 705-740.		1
638	Abstract LB-202: 14-3-3 σ turns TGF- β 's function from tumor suppressor to metastasis promoter in breast cancer by contextual changes of Smad partners from p53 to Gli2. , 2015, , .		1
639	Abstract 4710: p53 regulates epithelial-mesenchymal transition (EMT) and stem cell properties through modulation of miRNAs. , 2011, , .		1
640	Abstract 1438: Breast cancer metastasis suppressor 1 (BRMS1) suppresses attachment and spreading of breast cancer cells on 2D and 3D extracellular matrix components by altering focal adhesion-associated signaling. , 2011, , .		1
641	APOBEC3G promotes liver metastasis in an orthotopic mouse model of colorectal cancer and predicts human hepatic metastasis. Journal of Clinical Investigation, 2012, 122, 419-419.	8.2	1
642	Regulation of SETD2, a histone methyltransferase, in advanced clear cell renal cell carcinoma (ccRCC).. Journal of Clinical Oncology, 2012, 30, 368-368.	1.6	1
643	THE MICROFOCUS ASSAY SYSTEM (MFAS) - A SIMPLE QUANTITATIVE ASSAY TO IDENTIFY INHIBITORY DRUGS TARGETED AGAINST SPECIFIC ONCOGENES. Oncology Reports, 1994, 1, 37-41.	2.6	1
644	Abstract 5146: The histone demethylase KDM2A is a new promoter of tumorigenesis, drug target and negative prognostic biomarker for non-small cell lung cancer. , 2014, , .		1
645	Abstract 1027: Inhibition of c-MET upregulates PD-L1 related immune escape in lung adenocarcinoma. , 2020, , .		1
646	Selective expression of constitutively active pro-apoptotic protein BikDD gene in primary mammary tumors inhibits tumor growth and reduces tumor initiating cells. American Journal of Cancer Research, 2015, 5, 3624-34.	1.4	1
647	Multi-organ metastasis as destination for breast cancer cells guided by biomechanical architecture. American Journal of Cancer Research, 2021, 11, 2537-2567.	1.4	1
648	Ferroptosis: a promising target for cancer immunotherapy.. American Journal of Cancer Research, 2021, 11, 5856-5863.	1.4	1

#	ARTICLE	IF	CITATIONS
649	De-glycosylated membrane PD-L1 in tumor tissues as a biomarker for responsiveness to atezolizumab (Tecentriq) in advanced breast cancer patients.. American Journal of Cancer Research, 2022, 12, 123-137.	1.4	1
650	Repression of neu-induced clonogenicity by dimethylsulfoxide correlates with decreased levels of neu-encoded cell-surface p185 and changes in phosphotyrosine content of endogenous proteins. Cancer Letters, 1993, 68, 55-60.	7.2	0
651	ADP-Ribosylation Inhibitors Inhibit Cellular RNA Synthesis but Do Not Affect Expression of Manganous Superoxide Dismutase or Heat Shock Protein 70 in Tumor Necrosis Factor α -Sensitive and -Resistant Tumor Cells. Journal of Interferon and Cytokine Research, 1995, 15, 791-797.	1.2	0
652	When all the colonies are blue. Cancer Biology and Therapy, 2005, 4, 612-614.	3.4	0
653	1002. L1 Cell Adhesion Molecule, a Novel Target of Prostate Cancer Gene Therapy. Molecular Therapy, 2006, 13, S386.	8.2	0
654	The VEGF-C/Flt-4 Axis Promotes Invasion and Metastasis of Cancer Cells. Cancer Cell, 2007, 11, 207.	16.8	0
655	The VEGF-C/Flt-4 Axis Promotes Invasion and Metastasis of Cancer Cells. Cancer Cell, 2008, 14, 274-277.	16.8	0
656	Optofluidic single molecule flow proteometry. Proceedings of SPIE, 2009, , .	0.8	0
657	Dynamics of EGFR Trafficking from Membrane into Deep Cytoplasm Revealed by a Spatiotemporally Multiplexed 3D Tracking Microscope. Biophysical Journal, 2016, 110, 638a.	0.5	0
658	Mechanisms of Action and Resistance of Trastuzumab in Breast Cancer. Resistance To Targeted Anti-cancer Therapeutics, 2018, , 51-66.	0.1	0
659	Effect of Epithelial-Mesenchymal Transition on EGFR Dynamics Revealed by Single-Particle Tracking. Biophysical Journal, 2018, 114, 534a.	0.5	0
660	Abstract 4017: Identifying Protein-Protein Interactions in Single Protein Complex level by Microchannel Device. , 2010, , .		0
661	Abstract 263: p38 MAPK is required for EGFR nuclear translocation. , 2010, , .		0
662	Abstract 1086: RHA plays an important role in EGFR-mediated gene transcription in cancer cells. , 2011, , .		0
663	Abstract 721: Putative molecular mechanism contributing AZD6244 resistance in lung cancer. , 2011, , .		0
664	Abstract 4051: EGF receptor trafficking from the cell surface to the nucleus through the Golgi, ER, and nuclear envelope. , 2011, , .		0
665	Abstract 976: Hypoxic microenvironment promotes breast cancer stem cells through regulation of Polycomb protein expression. , 2011, , .		0
666	Abstract A57: The novel function of nuclear ErbB-2 in regulating transcription of rRNA genes. , 2011, , .		0

#	ARTICLE	IF	CITATIONS
667	Abstract 3290: A novel model of breast cancer metastasis: Killing two birds with one stone. , 2012, , .		0
668	Abstract 1035: SETD2, a histone methyltransferase, is misregulated in advanced clear cell renal cell carcinoma (ccRCC). , 2012, , .		0
669	Abstract 1230: Syntaxin 6- and microtubule-mediated intracellular trafficking contributes to Golgi and nuclear translocation of EGFR. , 2012, , .		0
670	Abstract 3036: Interaction of proliferation cell nuclear antigen (PCNA) with c-Abl in cell proliferation and response to DNA damages in breast cancer. , 2012, , .		0
671	Abstract 3465: The effect of ephrin-A1 on the resistance of photodynamic therapy in esophageal cancer cells. , 2012, , .		0
672	Abstract C171: Novel therapeutic strategies targeting the hedgehog signaling pathway and mTOR pathway in biliary tract cancer (BTC).. , 2013, , .		0
673	SUPPRESSED AUTOPHOSPHORYLATION AND TYROSINE KINASE-ACTIVITY IN REVERTANT CELL-LINES EXPRESSING RAT NEU ONCOGENE. Oncology Reports, 1994, 1, 895-902.	2.6	0
674	Translational Research in Breast Cancer. , 1999, , 345-356.		0
675	Abstract 2784: Targeting TGF- β 2 regulated E3 ligases: a novel therapeutic approach for primary liver cancer. , 2014, , .		0
676	Abstract 3896: The Hippo coactivator YAP1 upregulates SOX9 and endows cancer stem cell properties in non-transformed cells and esophageal cancer cells. , 2014, , .		0
677	Abstract B03: Cisplatin-resistant cells possess collateral sensitivity to folate antimetabolites. , 2015, , .		0
678	Abstract 5129: Model osteosarcoma by Li-Fraumeni syndrome patient-specific induced pluripotent stem cells. , 2015, , .		0
679	Abstract 5120: Using flow-proteomic platform to analyze individual signaling complexes in tumor tissue. , 2015, , .		0
680	Abstract 3298: ABL1 is required for Tie2-mediated DNA repair in brain tumor stem cells. , 2015, , .		0
681	Abstract 2895: Phosphorylation of EZH2 at T416 by CDK2 promotes development of mammary tumors with basal-like phenotype. , 2015, , .		0
682	Abstract 3900: Genomic landscape of human cancer reveals dysregulated TGF- β 2 signaling with prognostic significance. , 2015, , .		0
683	Abstract 1962: TGF- β 2/SMAD2 signaling drives tumor-progression via c-KIT/STAT3-signaling in advanced HCC. , 2015, , .		0
684	Abstract 3911: A positive feedback loop between TGF- β 2 and SCF mediates TGF- β 21 ligand overexpression in advanced hepatocellular carcinoma. , 2015, , .		0

#	ARTICLE	IF	CITATIONS
685	Nanofluidic Strategies for Cancer Research. RSC Nanoscience and Nanotechnology, 2016, , 114-149.	0.2	0
686	Abstract LB-119: Single-cell live imaging of paclitaxel-resistant cancer cell generation. , 2016, , .		0
687	Abstract LB-002: Methylation of the EGF receptor regulates signaling and therapeutic response. , 2016, , .		0
688	Abstract B47: Stabilization of programmed death ligand-1 by epidermal growth factor enhances cancer cell immune escape. , 2017, , .		0
689	Arginine methylation of EGFR in circulating tumor cells: A new biomarker for predicting resistance to anti-EGFR agents.. Journal of Clinical Oncology, 2017, 35, 3590-3590.	1.6	0
690	Abstract LB-131: Targeting expression of EZH2 with increased H3K27 trimethylation activity drives and synergizes with oncogene to promote mammary tumorigenesis in genetically engineered mouse models. , 2017, , .		0
691	Abstract 3: Targeting epigenetic modifiers in diffuse large B-cell lymphoma. , 2017, , .		0
692	Abstract 5854: TIE2-mediated epigenetic marks regulate therapeutic resistance of glioblastoma. , 2017, , .		0
693	Abstract 4713: Deubiquitination and stabilization of programmed cell death-ligand 1 by CSN5. , 2017, , .		0
694	Abstract 3028: Reactive oxygen species induced nuclear translocation of c-MET via INTERNET mechanism. , 2017, , .		0
695	Abstract 5606: Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1. , 2018, , .		0
696	Abstract 3205: Histone tyrosine phosphorylation determines glioblastoma cell survival. , 2018, , .		0
697	Abstract 845: c-MET nuclear transportation via membrane-bounded retrograde trafficking in breast cancer cells. , 2019, , .		0
698	Abstract LB-092: TKI insensitive role of EGFRconfers TKI resistance via PKC ζ . , 2019, , .		0
699	Abstract LB-258: EGFR and c-MET cooperate to enhance PARP inhibitor resistance in hepatocellular carcinoma. , 2019, , .		0
700	Abstract B090: Tyrosine 211 phosphorylation of PCNA: A new paradigm of linking cell proliferation to cancer stemness and metastasis. , 2019, , .		0
701	Abstract 5682: Synergism of PARP inhibitor and MET inhibitor in multiple cancer types with intrinsic and acquired PARP inhibitor resistances. , 2020, , .		0
702	Abstract 6527: Targeting glycosylated PD-1 induces potent anti-tumor immunity. , 2020, , .		0

#	ARTICLE	IF	CITATIONS
703	Abstract 5180: Nuclear receptor tyrosine kinase c-MET restrains efficacy of PARP inhibitor in pancreatic cancer cells. , 2020, , .		0
704	Abstract 4074: Reversing acquired PARPi resistance of TNBC through combined inhibition of cMet and EGFR. , 2020, , .		0
705	Antimetastasis. , 2005, , 287-298.		0
706	Trials and Tribulations in Developing Clinical Trials of Gene Therapy. , 2007, , 387-398.		0
707	Development of Therapeutic Genes for Breast Cancer Treatment. , 2007, , 435-446.		0
708	Safety and efficacy of quadrapeutics versus chemoradiation in head and neck carcinoma xenograft model. American Journal of Cancer Research, 2015, 5, 3534-47.	1.4	0
709	Glycosylation of Siglec15 promotes immunoescape and tumor growth. American Journal of Cancer Research, 2021, 11, 2291-2302.	1.4	0
710	NONO phase separation enhances DNA damage repair by accelerating nuclear EGFR-induced DNA-PK activation. American Journal of Cancer Research, 2021, 11, 2838-2852.	1.4	0
711	Dasatinib Increases MHCII Surface Levels and Can Synergize with Anti-PD1 Therapy to Increase the Anti-Tumor Effect in a Pre-Clinical Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Model. Blood, 2020, 136, 44-44.	1.4	0
712	Abstract 4122: The regulatory mechanism of PD-L1 level through ER-associated degradation. , 2019, , .		0
713	Shedding light on triple-negative breast cancer with Trop2-targeted antibody-drug conjugates.. American Journal of Cancer Research, 2022, 12, 1671-1685.	1.4	0